Gene Gene synonym Ensembl Gene description Chromosome Position Protein class Evidence Antibody Reliability (IH) Reliability (Mouse Brain) Reliability (IF) Subcellular location Prognostic p-value RNA cancer category RNA tissue category RNA TS RNA TS TPM TPM max in non-specific AASS LKRSDH, LORSDH ENSG00000008311 Aminoadipate-semialdehyde synthase 7 122075647-122144280 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA020637, HPA020728, HPA020734 Supported Validated Vesicles
Mitochondria Liver cancer:9.81e-4 (favourable) Expressed in all Mixed ovary: 30.6 ACADL ACAD4, LCAD ENSG00000115361 Acyl-CoA dehydrogenase, long chain 2 210187939-210225491 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA011990 Supported Supported Renal cancer:1.58e-11 (favourable) Group enriched Tissue enhanced thyroid gland: 31.9 prostate: 25.1 ACADM ACAD1, MCAD, MCADH ENSG00000117054 Acyl-CoA dehydrogenase, C-4 to C-12 straight chain 1 75724347-75787575 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA006198, HPA026542 Supported Validated Mitochondria Renal cancer:3.83e-8 (favourable), Colorectal cancer:7.30e-4 (favourable) Expressed in all Expressed in all kidney: 325.2 ACADS ACAD3, SCAD ENSG00000122971 Acyl-CoA dehydrogenase, C-2 to C-3 short chain 12 120725735-120740008 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA004799, CAB019284, HPA022271 Supported Supported Nucleoplasm
Mitochondria Renal cancer:3.33e-6 (favourable), Urothelial cancer:6.34e-5 (favourable), Liver cancer:2.43e-4 (favourable), Endometrial cancer:5.05e-4 (favourable), Glioma:9.94e-4 (unfavourable) Expressed in all Expressed in all duodenum: 83.5 ACADSB ACAD7, SBCAD ENSG00000196177 Acyl-CoA dehydrogenase, short/branched chain 10 123008979-123058311 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA041458 Supported Supported Mitochondria Renal cancer:6.37e-12 (favourable), Pancreatic cancer:3.40e-4 (favourable) Expressed in all Expressed in all liver: 186.7 ACADVL ACAD6, LCACD, VLCAD ENSG00000072778 Acyl-CoA dehydrogenase, very long chain 17 7217125-7225273 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA019006, HPA020595 Supported Supported Nucleus
Nucleoli
Mitochondria Pancreatic cancer:6.87e-4 (favourable) Expressed in all Expressed in all adrenal gland: 455.8 ACOX1 PALMCOX ENSG00000161533 Acyl-CoA oxidase 1, palmitoyl 17 75941507-75979363 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level CAB021094, HPA021192, HPA021195, HPA028759 Approved Validated Nucleus
Vesicles Renal cancer:5.25e-7 (favourable) Expressed in all Expressed in all liver: 98.4 ACOX2 BRCACOX, BRCOX, THCCox ENSG00000168306 Acyl-CoA oxidase 2, branched chain 3 58505136-58537319 Enzymes, Predicted intracellular proteins Evidence at protein level HPA038280, HPA064845 Approved Supported Vesicles
Mitochondria Tissue enhanced Tissue enhanced liver: 87.8 kidney: 42.3 ACOX3 ENSG00000087008 Acyl-CoA oxidase 3, pristanoyl 4 8366282-8440723 Enzymes, Predicted intracellular proteins Evidence at protein level HPA035840, HPA035841 Uncertain Approved Peroxisomes Endometrial cancer:2.16e-4 (favourable) Expressed in all Expressed in all esophagus: 22.3 ADH1A ADH1 ENSG00000187758 Alcohol dehydrogenase 1A (class I), alpha polypeptide 4 99276367-99291028 Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB009562, HPA047814, HPA060902 Supported Approved Plasma membrane
Cytosol Liver cancer:2.38e-4 (favourable) Tissue enriched Tissue enriched 134 liver: 1364.4 gallbladder: 10.2 ADH1B ADH2 ENSG00000196616 Alcohol dehydrogenase 1B (class I), beta polypeptide 4 99304964-99321401 Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA047814, HPA060902 Supported Approved Plasma membrane
Cytosol Renal cancer:7.87e-4 (unfavourable) Tissue enriched Group enriched 6 adipose tissue: 1534.1;liver: 2889.4 lung: 371.7 ADH1C ADH3 ENSG00000248144 Alcohol dehydrogenase 1C (class I), gamma polypeptide 4 99336492-99353027 Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA047814, HPA060902 Supported Approved Nucleoplasm
Plasma membrane
Cytosol Lung cancer:2.99e-4 (favourable), Liver cancer:4.55e-4 (favourable) Tissue enriched Tissue enhanced duodenum: 522.4;liver: 886.9;stomach: 478.6 colon: 281.0 ADH4 ADH-2 ENSG00000198099 Alcohol dehydrogenase 4 (class II), pi polypeptide 4 99123657-99157792 Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA020525 Supported Uncertain Nucleus
Cytosol Liver cancer:7.08e-6 (favourable) Tissue enriched Tissue enriched 15 liver: 2627.7 duodenum: 170.9 ADH5 ADH-3, ADHX, FDH ENSG00000197894 Alcohol dehydrogenase 5 (class III), chi polypeptide 4 99070978-99088801 Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA044578, HPA061919 Approved Renal cancer:4.58e-10 (favourable), Endometrial cancer:9.90e-5 (favourable), Melanoma:3.54e-4 (unfavourable) Expressed in all Expressed in all endometrium: 197.0 ADH7 ADH-4 ENSG00000196344 Alcohol dehydrogenase 7 (class IV), mu or sigma polypeptide 4 99412261-99435737 Enzymes, Predicted intracellular proteins Evidence at protein level HPA039695 Supported Supported Plasma membrane
Cytosol Group enriched Tissue enriched 6 esophagus: 216.3 tonsil: 35.9 ADHFE1 ADHFe1, FLJ32430 ENSG00000147576 Alcohol dehydrogenase, iron containing, 1 8 66430185-66471601 Enzymes, Predicted intracellular proteins Evidence at protein level HPA023062 Approved Approved Vesicles Renal cancer:4.55e-5 (favourable), Breast cancer:5.76e-5 (favourable), Liver cancer:9.90e-5 (favourable) Mixed Mixed liver: 14.3 ADI1 APL1, ARD, FLJ10913, HMFT1638, MTCBP-1, mtnD, SIPL ENSG00000182551 Acireductone dioxygenase 1 2 3497361-3519736 Enzymes, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA035403, HPA035404 Approved Supported Nucleoplasm
Golgi apparatus Expressed in all Expressed in all liver: 228.6 ADO C10orf22, FLJ14547 ENSG00000181915 2-aminoethanethiol (cysteamine) dioxygenase 10 62804857-62808483 Enzymes, Predicted intracellular proteins Evidence at protein level HPA039194, HPA040437 Approved Liver cancer:8.01e-5 (unfavourable) Expressed in all Expressed in all testis: 70.2 AGMO FLJ16237, TMEM195 ENSG00000187546 Alkylglycerol monooxygenase 7 15200318-15562015 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA057900 Uncertain Vesicles Tissue enriched Tissue enhanced liver: 63.6 epididymis: 17.5 AKR1A1 ALR, DD3 ENSG00000117448 Aldo-keto reductase family 1, member A1 (aldehyde reductase) 1 45550543-45570049 Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB006246, HPA017919, HPA019649, HPA027734 Approved Supported Nucleoplasm
Cytosol Cervical cancer:2.66e-6 (favourable), Endometrial cancer:2.92e-4 (favourable) Expressed in all Expressed in all kidney: 377.7 AKR1B1 ALDR1, AR ENSG00000085662 Aldo-keto reductase family 1, member B1 (aldose reductase) 7 134442350-134459284 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA026425, CAB027391, CAB047353, HPA052751 Supported Supported Nucleus
Cytosol Stomach cancer:2.44e-5 (unfavourable), Urothelial cancer:7.00e-4 (unfavourable) Expressed in all Tissue enriched 6 adrenal gland: 2498.2 seminal vesicle: 444.1 AKR1B15 ENSG00000227471 Aldo-keto reductase family 1, member B15 7 134549136-134579875 Enzymes, Predicted intracellular proteins Evidence at protein level HPA020280, HPA073633 Uncertain Supported Plasma membrane
Cytosol Liver cancer:1.80e-5 (unfavourable), Urothelial cancer:1.90e-5 (unfavourable), Head and neck cancer:8.36e-4 (favourable) Mixed Tissue enriched 12 breast: 176.5 duodenum: 14.1 AKR1C1 DD1, DDH, DDH1, HAKRC, MBAB ENSG00000187134 Aldo-keto reductase family 1, member C1 10 4963253-5107522 Enzymes, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB047303, HPA068265 Uncertain Supported Endoplasmic reticulum
Cytosol Renal cancer:8.03e-9 (favourable), Liver cancer:1.56e-4 (unfavourable), Cervical cancer:3.05e-4 (favourable) Tissue enhanced Expressed in all liver: 406.4 AKR1C2 BABP, DD, DD2, DDH2, HAKRD, MCDR2, TDD ENSG00000151632 Aldo-keto reductase family 1, member C2 10 4922564-5135226 Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level CAB047304, HPA068265 Approved Approved Nucleus
Nucleoli fibrillar center
Endoplasmic reticulum
Cytosol Group enriched Group enriched 5 adipose tissue: 352.3;breast: 122.0;esophagus: 118.4;gallbladder: 189.9;liver: 186.5;stomach: 138.5;urinary bladder: 186.3 duodenum: 33.7 AKR1C3 DDX, HAKRB, HSD17B5, KIAA0119, PGFS ENSG00000196139 Aldo-keto reductase family 1, member C3 10 5035354-5107686 Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB010874, HPA068265 Approved Approved Nucleus
Nucleoli fibrillar center
Endoplasmic reticulum
Cytosol Renal cancer:1.22e-4 (unfavourable), Liver cancer:1.96e-4 (unfavourable) Expressed in all Expressed in all duodenum: 154.7 AKR1C4 3-alpha-HSD, C11, CDR, CHDR, DD4, HAKRA, MGC22581 ENSG00000198610 Aldo-keto reductase family 1, member C4 10 5195462-5218949 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA044720, HPA068265 Uncertain Uncertain Nucleus
Nucleoli fibrillar center
Endoplasmic reticulum
Cytosol Tissue enriched Tissue enriched 6 liver: 358.9 gallbladder: 64.5 AKR1D1 SRD5B1 ENSG00000122787 Aldo-keto reductase family 1, member D1 7 138002324-138117986 Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level HPA057002 Supported Approved Nucleoplasm
Cytosol Liver cancer:9.91e-5 (favourable) Tissue enriched Tissue enriched 32 liver: 229.0 breast: 7.1 AKR1E2 AKR1CL2, AKRDC1, MGC10612 ENSG00000165568 Aldo-keto reductase family 1, member E2 10 4786629-4848062 Enzymes, Predicted intracellular proteins Evidence at protein level HPA037821, HPA037822 Uncertain Validated Nucleoplasm
Golgi apparatus Mixed Tissue enhanced testis: 30.0 thyroid gland: 6.1 AKR7A2 AFAR ENSG00000053371 Aldo-keto reductase family 7, member A2 1 19303965-19312146 Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB032587, CAB032841, HPA064638 Supported Supported Cytosol Renal cancer:2.67e-4 (favourable), Urothelial cancer:8.59e-4 (unfavourable) Expressed in all Expressed in all duodenum: 84.1 ALDH18A1 GSAS, P5CS, PYCS ENSG00000059573 Aldehyde dehydrogenase 18 family, member A1 10 95605929-95656706 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA008333, HPA012604 Approved Validated Mitochondria Renal cancer:3.60e-9 (unfavourable), Endometrial cancer:4.20e-4 (favourable) Expressed in all Expressed in all duodenum: 92.0 ALDH1A1 ALDH1, PUMB1, RALDH1 ENSG00000165092 Aldehyde dehydrogenase 1 family, member A1 9 72900662-73080442 Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA002123, CAB020690 Approved Approved Validated Cytosol Cervical cancer:7.77e-5 (favourable) Expressed in all Expressed in all liver: 758.5 ALDH1A2 RALDH2 ENSG00000128918 Aldehyde dehydrogenase 1 family, member A2 15 57953424-58497866 Enzymes, Predicted intracellular proteins Evidence at protein level HPA010022 Approved Mixed Tissue enhanced endometrium: 117.2;fallopian tube: 107.1 testis: 96.5 ALDH1A3 ALDH6, RALDH3 ENSG00000184254 Aldehyde dehydrogenase 1 family, member A3 15 100877714-100916626 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA046271, HPA064749 Approved Validated Nucleus
Cytosol Group enriched Tissue enhanced prostate: 209.6 adipose tissue: 74.0 ALDH1B1 ALDH5, ALDHX ENSG00000137124 Aldehyde dehydrogenase 1 family, member B1 9 38392664-38398661 Enzymes, Predicted intracellular proteins Evidence at protein level HPA021037 Approved Supported Nucleoplasm
Vesicles
Mitochondria Thyroid cancer:1.17e-5 (unfavourable), Renal cancer:2.05e-4 (favourable) Expressed in all Expressed in all smooth muscle: 176.4 ALDH1L1 10-fTHF, FTHFD ENSG00000144908 Aldehyde dehydrogenase 1 family, member L1 3 126103562-126197994 Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA036900, HPA050139 Approved Supported Cytosol Renal cancer:2.42e-8 (favourable) Tissue enhanced Tissue enhanced kidney: 123.5;liver: 191.5 adipose tissue: 82.2 ALDH1L2 FLJ38508, mtFDH ENSG00000136010 Aldehyde dehydrogenase 1 family, member L2 12 105019784-105084577 Enzymes, Predicted intracellular proteins Evidence at protein level HPA039481 Uncertain Supported Mitochondria Mixed Mixed cervix, uterine: 8.3 ALDH2 ENSG00000111275 Aldehyde dehydrogenase 2 family (mitochondrial) 12 111766887-111817529 Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA051065 Approved Liver cancer:3.95e-7 (favourable), Renal cancer:5.24e-6 (favourable), Endometrial cancer:2.63e-4 (favourable), Urothelial cancer:7.71e-4 (unfavourable) Expressed in all Expressed in all liver: 440.7 ALDH3A1 ALDH3 ENSG00000108602 Aldehyde dehydrogenase 3 family, member A1 17 19737984-19748943 Enzymes, Predicted intracellular proteins Evidence at protein level CAB045957, HPA051150, HPA063783 Supported Validated Vesicles
Plasma membrane
Cytosol Head and neck cancer:7.55e-5 (favourable) Mixed Group enriched 7 esophagus: 407.6;skin: 84.5;stomach: 210.9 tonsil: 32.2 ALDH3A2 ALDH10, ALDH3A2, FALDH , SLS ENSG00000072210 Aldehyde dehydrogenase 3 family, member A2 17 19648136-19677598 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA014769, CAB020692 Approved Renal cancer:3.85e-8 (favourable) Expressed in all Expressed in all adrenal gland: 179.9 ALDH3B1 ALDH7 ENSG00000006534 Aldehyde dehydrogenase 3 family, member B1 11 68008578-68029282 Enzymes, Predicted intracellular proteins Evidence at protein level HPA038525 Uncertain Colorectal cancer:1.18e-4 (unfavourable), Pancreatic cancer:6.07e-4 (unfavourable) Expressed in all Tissue enhanced fallopian tube: 63.7;lung: 67.9 bone marrow: 30.8 ALDH3B2 ALDH8 ENSG00000132746 Aldehyde dehydrogenase 3 family, member B2 11 67662162-67681200 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA045132 Approved Mixed Group enriched 5 breast: 88.2;esophagus: 103.8;skin: 122.4 tonsil: 19.7 ALDH4A1 ALDH4, P5CDh ENSG00000159423 Aldehyde dehydrogenase 4 family, member A1 1 18871430-18902781 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level CAB004645, HPA006401 Approved Cervical cancer:5.06e-4 (favourable) Expressed in all Tissue enhanced kidney: 184.9;liver: 108.1 adipose tissue: 63.7 ALDH5A1 SSADH, SSDH ENSG00000112294 Aldehyde dehydrogenase 5 family, member A1 6 24494852-24537207 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA029715, HPA029716 Supported Validated Mitochondria Liver cancer:7.61e-6 (favourable), Renal cancer:3.68e-4 (favourable), Ovarian cancer:6.20e-4 (favourable) Expressed in all Expressed in all liver: 46.8 ALDH6A1 MMSDH ENSG00000119711 Aldehyde dehydrogenase 6 family, member A1 14 74056850-74084493 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA029072, HPA029073, HPA029074, HPA029075 Supported Validated Mitochondria Renal cancer:2.00e-15 (favourable), Lung cancer:4.22e-4 (favourable) Expressed in all Expressed in all kidney: 386.6 ALDH7A1 ATQ1, EPD, PDE ENSG00000164904 Aldehyde dehydrogenase 7 family, member A1 5 126541841-126595418 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA023296 Supported Supported Mitochondria
Cytosol Renal cancer:3.08e-4 (favourable) Expressed in all Expressed in all kidney: 162.4 ALDH9A1 ALDH4, ALDH7, ALDH9, E3 ENSG00000143149 Aldehyde dehydrogenase 9 family, member A1 1 165662216-165698863 Enzymes, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA006077, HPA010873 Approved Approved Cytosol Pancreatic cancer:4.56e-4 (favourable) Expressed in all Expressed in all thyroid gland: 205.3 ALKBH1 ABH, alkB, ALKBH, hABH ENSG00000100601 AlkB homolog 1, histone H2A dioxygenase 14 77672404-77708020 Enzymes, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA044087 Approved Renal cancer:1.80e-4 (favourable) Expressed in all Mixed placenta: 5.6 ALKBH2 ABH2, MGC90512 ENSG00000189046 AlkB homolog 2, alpha-ketoglutarate-dependent dioxygenase 12 109088188-109093631 Enzymes, Predicted intracellular proteins Evidence at protein level CAB011198, HPA045392, HPA051976 Approved Validated Nucleus Renal cancer:1.41e-5 (unfavourable), Breast cancer:6.67e-5 (favourable), Urothelial cancer:8.67e-4 (favourable) Expressed in all Expressed in all skin: 27.1 ALOX12 12S-LOX ENSG00000108839 Arachidonate 12-lipoxygenase 17 6996065-7010736 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA010691, CAB019287 Supported Supported Nuclear speckles
Cytosol Mixed Group enriched 5 esophagus: 50.5;skin: 26.0 tonsil: 7.1 ALOX15 15-LOX-1 ENSG00000161905 Arachidonate 15-lipoxygenase 17 4630902-4642294 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level CAB004962, CAB004963, HPA013859 Approved Mixed Tissue enhanced fallopian tube: 19.3;lung: 9.9 breast: 4.6 ALOX15B 15-LOX-2 ENSG00000179593 Arachidonate 15-lipoxygenase, type B 17 8039017-8049134 Enzymes, Predicted intracellular proteins Evidence at protein level HPA010562 Approved Cytosol Expressed in all Group enriched 5 breast: 142.3;prostate: 122.6 lung: 26.1 ALOX5 5-LOX ENSG00000012779 Arachidonate 5-lipoxygenase 10 45374176-45446119 Enzymes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level HPA071285 Supported Supported Nucleoplasm Renal cancer:1.80e-5 (unfavourable), Urothelial cancer:7.18e-4 (favourable) Expressed in all Tissue enhanced lung: 41.4 bone marrow: 28.9 AOC1 ABP1, DAO ENSG00000002726 Amine oxidase, copper containing 1 7 150824627-150861504 Enzymes, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA031032, HPA031033 Approved Prostate cancer:1.71e-4 (favourable) Group enriched Tissue enhanced placenta: 711.7;small intestine: 257.2 duodenum: 190.7 AOC2 DAO2, RAO ENSG00000131480 Amine oxidase, copper containing 2 (retina-specific) 17 42844600-42850707 Enzymes, Predicted secreted proteins Evidence at protein level HPA057779 Uncertain Urothelial cancer:2.47e-4 (favourable) Tissue enhanced Tissue enhanced adipose tissue: 6.2;testis: 5.9 spleen: 1.2 AOC3 HPAO, VAP-1, VAP1 ENSG00000131471 Amine oxidase, copper containing 3 17 42851184-42858130 Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA000980, CAB025797 Supported Approved Golgi apparatus
Cytosol Renal cancer:1.79e-5 (unfavourable), Colorectal cancer:3.68e-4 (unfavourable), Urothelial cancer:6.98e-4 (unfavourable) Expressed in all Tissue enhanced adipose tissue: 449.0 smooth muscle: 203.0 AOX1 AO, AOH1 ENSG00000138356 Aldehyde oxidase 1 2 200585868-200677064 Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA040199, HPA040215 Approved Supported Nuclear bodies
Cytosol Renal cancer:6.05e-5 (favourable) Tissue enriched Group enriched 5 adrenal gland: 370.6;kidney: 96.7;liver: 432.0 ovary: 56.6 ASPDH ENSG00000204653 Aspartate dehydrogenase domain containing 19 50511600-50514690 Enzymes, Predicted intracellular proteins Evidence at protein level HPA042631, HPA042654 Approved Tissue enriched Group enriched 7 cerebral cortex: 17.9;duodenum: 7.1;kidney: 27.9;liver: 34.6 adrenal gland: 3.3 ASPH BAH, CASQ2BP1, HAAH, JCTN ENSG00000198363 Aspartate beta-hydroxylase 8 61500556-61714640 Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA055161, HPA059303 Uncertain Supported Endoplasmic reticulum Renal cancer:1.57e-5 (unfavourable), Cervical cancer:8.07e-5 (unfavourable), Pancreatic cancer:1.75e-4 (unfavourable), Lung cancer:3.61e-4 (unfavourable), Thyroid cancer:4.24e-4 (unfavourable) Expressed in all Expressed in all adipose tissue: 394.0 BBOX1 BBH, BBOX, G-BBH, gamma-BBH ENSG00000129151 Butyrobetaine (gamma), 2-oxoglutarate dioxygenase (gamma-butyrobetaine hydroxylase) 1 11 27040725-27127809 Enzymes, Predicted intracellular proteins Evidence at protein level HPA007600, HPA027823 Supported Approved Renal cancer:1.45e-5 (favourable), Endometrial cancer:6.65e-4 (unfavourable) Group enriched Tissue enriched 7 kidney: 469.2 liver: 66.0 BCKDHA MSU, OVD1A ENSG00000248098 Branched chain keto acid dehydrogenase E1, alpha polypeptide 19 41397460-41431345 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA036640 Supported Renal cancer:5.33e-10 (favourable), Thyroid cancer:3.27e-5 (unfavourable), Head and neck cancer:9.37e-4 (favourable) Expressed in all Expressed in all thyroid gland: 56.6 BCKDHB ENSG00000083123 Branched chain keto acid dehydrogenase E1, beta polypeptide 6 80106647-80346270 Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins Evidence at protein level HPA031580 Approved Renal cancer:5.54e-9 (favourable) Expressed in all Expressed in all liver: 39.8 BCO1 BCDO, BCDO1, BCMO, BCMO1, FLJ10730 ENSG00000135697 Beta-carotene oxygenase 1 16 81238448-81291142 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA043811 Uncertain Actin filaments
Microtubule organizing center Mixed Tissue enhanced duodenum: 8.9;small intestine: 15.1 kidney: 3.3 BCO2 B-DIOX-II, BCDO2, FLJ34464 ENSG00000197580 Beta-carotene oxygenase 2 11 112175467-112224699 Enzymes, Predicted intracellular proteins Evidence at protein level HPA039825, HPA040695 Uncertain Mixed Tissue enhanced heart muscle: 21.5;liver: 25.6 adrenal gland: 17.0 BDH1 BDH, SDR9C1 ENSG00000161267 3-hydroxybutyrate dehydrogenase, type 1 3 197509783-197573323 Candidate cardiovascular disease genes, Enzymes, Predicted intracellular proteins Evidence at protein level HPA030947, HPA058709 Approved Validated Mitochondria Renal cancer:7.12e-8 (favourable), Liver cancer:9.86e-7 (favourable), Cervical cancer:1.09e-4 (favourable) Expressed in all Tissue enriched 6 liver: 168.8 colon: 27.4 BDH2 DHRS6, FLJ13261, PRO20933, SDR15C1, UCPA-OR, UNQ6308 ENSG00000164039 3-hydroxybutyrate dehydrogenase, type 2 4 103079435-103099883 Enzymes, Predicted intracellular proteins Evidence at protein level HPA036028, HPA036029 Supported Supported Cytosol Renal cancer:4.45e-13 (favourable), Lung cancer:1.20e-4 (favourable), Endometrial cancer:5.21e-4 (favourable), Thyroid cancer:7.75e-4 (favourable) Expressed in all Expressed in all kidney: 452.1 BLVRA BLVR ENSG00000106605 Biliverdin reductase A 7 43758680-43807342 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA019709, HPA042865, HPA054322 Approved Supported Cytosol Lung cancer:8.65e-4 (favourable) Expressed in all Expressed in all epididymis: 155.8 BLVRB FLR, SDR43U1 ENSG00000090013 Biliverdin reductase B 19 40447789-40465840 Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA041698, HPA041937 Supported Supported Nucleoplasm
Plasma membrane
Cytosol Pancreatic cancer:3.90e-4 (unfavourable) Expressed in all Expressed in all bone marrow: 339.1 C14orf169 FLJ21802, MAPJD, NO66 ENSG00000170468 Chromosome 14 open reading frame 169 14 73490964-73493392 Enzymes, Predicted intracellular proteins Evidence at protein level HPA003730 Supported Nucleoli Expressed in all Expressed in all testis: 17.7 CAT ENSG00000121691 Catalase 11 34438925-34472062 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB001515, HPA051282, HPA055838 Supported Supported Vesicles
Cytosol Renal cancer:1.96e-8 (favourable), Liver cancer:9.67e-4 (favourable) Expressed in all Expressed in all liver: 624.4 CBR1 CBR, SDR21C1 ENSG00000159228 Carbonyl reductase 1 21 36069941-36073166 Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA018433 Approved Approved Nucleus
Cytosol Breast cancer:2.18e-4 (favourable), Renal cancer:4.75e-4 (favourable) Expressed in all Expressed in all duodenum: 560.1 CBR3 SDR21C2 ENSG00000159231 Carbonyl reductase 3 21 36134912-36146566 Enzymes, Predicted intracellular proteins Evidence at protein level HPA018434 Uncertain Supported Nucleoplasm
Cytosol Renal cancer:5.95e-6 (unfavourable) Expressed in all Mixed skin: 20.7 CDO1 ENSG00000129596 Cysteine dioxygenase type 1 5 115804733-115816954 Enzymes, Predicted intracellular proteins Evidence at protein level HPA036573, HPA057503 Supported Uncertain Nucleoplasm Liver cancer:1.91e-5 (favourable) Group enriched Tissue enhanced epididymis: 135.2;liver: 209.6 adipose tissue: 103.7 CHDH ENSG00000016391 Choline dehydrogenase 3 53812335-53846390 Enzymes, Predicted intracellular proteins Evidence at protein level HPA036633, HPA058130 Supported Renal cancer:1.88e-8 (favourable) Mixed Tissue enhanced kidney: 39.9 small intestine: 16.7 CP ENSG00000047457 Ceruloplasmin (ferroxidase) 3 149162410-149222055 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA001834, CAB008591 Supported Renal cancer:1.14e-7 (unfavourable) Tissue enhanced Tissue enriched 10 liver: 916.4 cervix, uterine: 95.6 CPOX CPO, CPX, HCP ENSG00000080819 Coproporphyrinogen oxidase 3 98521132-98593723 Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA015736, HPA054448 Validated Mitochondria Renal cancer:1.04e-5 (unfavourable) Expressed in all Expressed in all bone marrow: 25.5 CRYL1 GDH, lambda-CRY, MGC149525, MGC149526 ENSG00000165475 Crystallin, lambda 1 13 20403667-20525857 Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA040403 Supported Approved Nucleus
Nucleoli
Golgi apparatus
Plasma membrane Renal cancer:2.30e-9 (favourable), Endometrial cancer:1.76e-5 (favourable) Expressed in all Expressed in all kidney: 335.8 CRYM DFNA40 ENSG00000103316 Crystallin, mu 16 21238874-21303083 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA019086, HPA030619 Supported Supported Cytosol Tissue enhanced Group enriched 6 cerebral cortex: 102.6;heart muscle: 98.1;kidney: 56.5;prostate: 52.7;urinary bladder: 30.8 lung: 11.5 CRYZ ENSG00000116791 Crystallin, zeta (quinone reductase) 1 74705482-74733408 Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA021921, HPA023290 Approved Supported Cytosol Expressed in all Expressed in all kidney: 342.7 CYB5R1 humb5R2, NQO3A2 ENSG00000159348 Cytochrome b5 reductase 1 1 202961869-202967280 Enzymes, Predicted intracellular proteins Evidence at protein level HPA010641, HPA014147 Supported Uncertain Nucleoli
Mitochondria
Cytosol Endometrial cancer:1.14e-4 (favourable) Expressed in all Expressed in all skeletal muscle: 183.8 CYB5R2 ENSG00000166394 Cytochrome b5 reductase 2 11 7665100-7677222 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA038962 Approved Approved Nucleoplasm
Golgi apparatus Mixed Tissue enhanced testis: 226.8 parathyroid gland: 78.3 CYB5R3 DIA1 ENSG00000100243 Cytochrome b5 reductase 3 22 42617840-42649568 Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA001566 Approved Validated Endoplasmic reticulum Liver cancer:2.13e-5 (unfavourable) Expressed in all Expressed in all adipose tissue: 336.2 CYB5R4 b5+b5R, dJ676J13.1, NCB5OR ENSG00000065615 Cytochrome b5 reductase 4 6 83859643-83967424 Enzymes, Predicted intracellular proteins Evidence at protein level HPA018992 Approved Expressed in all Expressed in all testis: 22.5 CYB5RL LOC606495 ENSG00000215883 Cytochrome b5 reductase-like 1 54172336-54200036 Enzymes, Predicted intracellular proteins Evidence at protein level HPA042671, HPA060463 Approved Validated Nucleoplasm Mixed Mixed thyroid gland: 3.3 CYP11A1 CYP11A, P450SCC ENSG00000140459 Cytochrome P450, family 11, subfamily A, polypeptide 1 15 74337759-74367740 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA016436 Supported Mixed Tissue enriched 11 adrenal gland: 752.7 testis: 68.6 CYP11B1 CPN1, CYP11B, FHI, P450C11 ENSG00000160882 Cytochrome P450, family 11, subfamily B, polypeptide 1 8 142872356-142879846 Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level HPA049171, HPA056348, HPA057752 Supported Not detected Tissue enriched 936 adrenal gland: 1879.5 testis: 2.0 CYP11B2 ALDOS, CPN2, CYP11B, CYP11BL, P-450C18, P450aldo ENSG00000179142 Cytochrome P450, family 11, subfamily B, polypeptide 2 8 142910559-142917843 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA049171, HPA056348, HPA057752 Supported Not detected Tissue enriched 899 adrenal gland: 126.7 testis: 0.1 CYP17A1 CPT7, CYP17, P450C17, S17AH ENSG00000148795 Cytochrome P450, family 17, subfamily A, polypeptide 1 10 102830531-102837533 Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA048533 Supported Renal cancer:5.43e-7 (favourable) Tissue enriched Tissue enriched 25 adrenal gland: 4500.7 testis: 180.3 CYP19A1 ARO, ARO1, aromatase, CPV1, CYAR, CYP19, P-450AROM ENSG00000137869 Cytochrome P450, family 19, subfamily A, polypeptide 1 15 51208057-51338610 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB000355, HPA051194 Supported Approved Vesicles Mixed Tissue enriched 14 placenta: 173.9 testis: 12.4 CYP1A1 CP11, CYP1, P1-450, P450-C, P450DX ENSG00000140465 Cytochrome P450, family 1, subfamily A, polypeptide 1 15 74719542-74725610 Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB018654 Uncertain Group enriched Group enriched 8 liver: 33.8;small intestine: 21.0;urinary bladder: 84.1 breast: 5.7 CYP1A2 CP12, P3-450 ENSG00000140505 Cytochrome P450, family 1, subfamily A, polypeptide 2 15 74748844-74756202 Cancer-related genes, Enzymes, Predicted membrane proteins Evidence at protein level CAB016531 Supported Group enriched Tissue enriched 168 liver: 268.7 thyroid gland: 1.5 CYP1B1 CP1B, GLC3A ENSG00000138061 Cytochrome P450, family 1, subfamily B, polypeptide 1 2 38066973-38109902 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB011705, HPA026863 Approved Uncertain Mitochondria Renal cancer:4.39e-6 (unfavourable), Urothelial cancer:2.76e-4 (unfavourable) Expressed in all Mixed fallopian tube: 75.4 CYP21A2 CA21H, CAH1, CPS1, CYP21, CYP21B, P450c21B ENSG00000231852 Cytochrome P450, family 21, subfamily A, polypeptide 2 6 32038265-32041670 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins Evidence at protein level HPA048979, HPA053371 Supported Tissue enhanced Tissue enriched 386 adrenal gland: 267.2 epididymis: 0.6 CYP24A1 CP24, CYP24, P450-CC24 ENSG00000019186 Cytochrome P450, family 24, subfamily A, polypeptide 1 20 54153449-54173973 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA022261, HPA063771 Supported Supported Nucleoplasm
Plasma membrane
Mitochondria Mixed Tissue enhanced endometrium: 24.8;urinary bladder: 52.7 placenta: 13.9 CYP27A1 CP27, CTX, CYP27 ENSG00000135929 Cytochrome P450, family 27, subfamily A, polypeptide 1 2 218781749-218815293 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA059155 Approved Validated Mitochondria Liver cancer:8.62e-6 (favourable), Breast cancer:1.05e-4 (favourable) Expressed in all Tissue enhanced liver: 278.5 lung: 98.4 CYP2A13 CPAD, CYP2A ENSG00000197838 Cytochrome P450, family 2, subfamily A, polypeptide 13 19 41088472-41096195 Enzymes, Predicted intracellular proteins Evidence at protein level HPA046713, HPA047262 Supported Tissue enriched Not detected testis: 0.4 CYP2A7 CYP2A ENSG00000198077 Cytochrome P450, family 2, subfamily A, polypeptide 7 19 40875439-40882752 Enzymes, Predicted secreted proteins Evidence at protein level CAB033510, HPA046713, HPA047262 Supported Group enriched Tissue enriched 113 liver: 60.8 breast: 0.5 CYP2C19 CPCJ, CYP2C, P450IIC19 ENSG00000165841 Cytochrome P450, family 2, subfamily C, polypeptide 19 10 94762624-94853260 Cancer-related genes, Enzymes, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA015066 Supported Not detected Tissue enhanced duodenum: 49.7;liver: 125.5 small intestine: 21.2 CYP2C8 CPC8 ENSG00000138115 Cytochrome P450, family 2, subfamily C, polypeptide 8 10 95036772-95069497 Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA013547, HPA013970, HPA015066 Supported Pancreatic cancer:9.82e-4 (favourable) Tissue enriched Tissue enriched 152 liver: 1121.7 gallbladder: 7.3 CYP2C9 CYP2C10, P450IIC9 ENSG00000138109 Cytochrome P450, family 2, subfamily C, polypeptide 9 10 94938658-94989390 Enzymes, Predicted secreted proteins Evidence at protein level HPA015066, CAB016123 Supported Liver cancer:2.83e-6 (favourable) Tissue enriched Tissue enriched 7 liver: 959.9 duodenum: 140.6 CYP2D6 CPD6, CYP2D, CYP2D7AP, CYP2D7BP, CYP2D7P2, CYP2D8P2, CYP2DL1, P450-DB1, P450C2D ENSG00000100197 Cytochrome P450, family 2, subfamily D, polypeptide 6 22 42126499-42130906 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA045223 Supported Uncertain Golgi apparatus Tissue enriched Tissue enhanced liver: 11.4;small intestine: 13.2 duodenum: 3.9 CYP2E1 CYP2E ENSG00000130649 Cytochrome P450, family 2, subfamily E, polypeptide 1 10 133520406-133561220 Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA009128, HPA029564 Supported Tissue enriched Tissue enriched 155 liver: 5312.8 tonsil: 34.3 CYP2R1 ENSG00000186104 Cytochrome P450, family 2, subfamily R, polypeptide 1 11 14877440-14892252 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA042949 Approved Renal cancer:2.86e-4 (unfavourable) Expressed in all Mixed skin: 8.1 CYP2S1 ENSG00000167600 Cytochrome P450, family 2, subfamily S, polypeptide 1 19 41193049-41207539 Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA049227 Approved Endoplasmic reticulum Renal cancer:1.60e-6 (unfavourable) Expressed in all Tissue enhanced duodenum: 99.4;small intestine: 70.0;stomach: 113.4 colon: 26.4 CYP2U1 SPG49 ENSG00000155016 Cytochrome P450, family 2, subfamily U, polypeptide 1 4 107931369-107953457 Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA041622, HPA046754, HPA064827 Uncertain Approved Nucleoplasm
Golgi apparatus
Vesicles Renal cancer:2.75e-5 (favourable), Stomach cancer:6.97e-4 (unfavourable) Expressed in all Mixed prostate: 15.7 CYP3A4 CYP3A3 ENSG00000160868 Cytochrome P450, family 3, subfamily A, polypeptide 4 7 99756960-99784265 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB033671, HPA072245 Supported Uncertain Cytosol Tissue enriched Group enriched 200 duodenum: 849.6;liver: 2446.6;small intestine: 990.4 adrenal gland: 7.1 CYP3A43 ENSG00000021461 Cytochrome P450, family 3, subfamily A, polypeptide 43 7 99828013-99866102 Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA066463, HPA072245 Supported Uncertain Cytosol Liver cancer:3.41e-4 (favourable) Tissue enriched Tissue enriched 14 liver: 22.4 testis: 1.5 CYP3A5 CP35, P450PCN3, PCN3 ENSG00000106258 Cytochrome P450, family 3, subfamily A, polypeptide 5 7 99648194-99679998 Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA072245 Uncertain Cytosol Liver cancer:3.72e-5 (favourable) Tissue enhanced Tissue enhanced duodenum: 117.9;liver: 93.1;small intestine: 191.3 stomach: 79.3 CYP3A7 CP37, P450-HFLA ENSG00000160870 Cytochrome P450, family 3, subfamily A, polypeptide 7 7 99705037-99735196 Enzymes, Predicted membrane proteins Evidence at protein level HPA072245 Uncertain Cytosol Tissue enriched Tissue enriched 14 liver: 143.0 gallbladder,kidney: 9.8 CYP3A7-CYP3A51P ENSG00000282301 CYP3A7-CYP3A51P readthrough 7 99684957-99735102 Enzymes, Predicted membrane proteins Evidence at protein level HPA072245 Uncertain Cytosol Tissue enhanced liver: 7.4 gallbladder: 1.9 CYP46A1 CYP46 ENSG00000036530 Cytochrome P450, family 46, subfamily A, polypeptide 1 14 99684304-99727301 Enzymes, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA040702 Uncertain Tissue enriched Tissue enriched 19 cerebral cortex: 64.3 heart muscle: 3.3 CYP4B1 ENSG00000142973 Cytochrome P450, family 4, subfamily B, polypeptide 1 1 46757838-46819413 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA004331 Approved Supported Vesicles Cervical cancer:5.99e-4 (favourable) Tissue enhanced Tissue enriched 5 lung: 371.8 fallopian tube: 71.5 CYP4F11 ENSG00000171903 Cytochrome P450, family 4, subfamily F, polypeptide 11 19 15912367-15934867 Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA017265, CAB033648, HPA058960 Supported Breast cancer:4.05e-4 (favourable), Pancreatic cancer:9.28e-4 (unfavourable) Mixed Tissue enhanced gallbladder: 29.6;liver: 32.7;small intestine: 26.8 epididymis: 19.8 CYP4F2 ENSG00000186115 Cytochrome P450, family 4, subfamily F, polypeptide 2 19 15878023-15898120 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA014048, HPA017265, HPA058960 Supported Tissue enriched Group enriched 6 duodenum: 80.4;epididymis: 27.5;kidney: 39.1;liver: 84.6;small intestine: 86.1 prostate: 10.6 CYP4F3 CYP4F, LTB4H ENSG00000186529 Cytochrome P450, family 4, subfamily F, polypeptide 3 19 15615617-15662825 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA058960 Approved Tissue enhanced Tissue enhanced bone marrow: 53.2;liver: 98.0 kidney: 29.2 CYP4F8 ENSG00000186526 Cytochrome P450, family 4, subfamily F, polypeptide 8 19 15615218-15630638 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA058960 Approved Group enriched Tissue enriched 51 seminal vesicle: 145.8 prostate: 2.8 CYP4V2 CYP4AH1 ENSG00000145476 Cytochrome P450, family 4, subfamily V, polypeptide 2 4 186191520-186213456 Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA029122 Approved Approved Nuclear speckles Renal cancer:1.49e-7 (favourable), Liver cancer:1.85e-4 (favourable), Endometrial cancer:5.86e-4 (favourable) Expressed in all Tissue enhanced parathyroid gland: 63.8 liver: 47.3 CYP4X1 MGC40051 ENSG00000186377 Cytochrome P450, family 4, subfamily X, polypeptide 1 1 47023568-47050751 Enzymes, Predicted membrane proteins Evidence at protein level HPA017661 Approved Mixed Tissue enhanced cervix, uterine: 52.7 breast: 18.6 CYP51A1 CP51, CYP51, CYPL1, LDM, P450-14DM, P450L1 ENSG00000001630 Cytochrome P450, family 51, subfamily A, polypeptide 1 7 92112151-92142952 Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA041325, HPA043508 Approved Validated Endoplasmic reticulum Cervical cancer:6.12e-4 (unfavourable) Expressed in all Expressed in all testis: 175.2 CYP7B1 SPG5A ENSG00000172817 Cytochrome P450, family 7, subfamily B, polypeptide 1 8 64587763-64798761 Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA017761 Uncertain Mixed Tissue enhanced parathyroid gland: 39.6 thyroid gland: 22.3 DAO DAMOX ENSG00000110887 D-amino-acid oxidase 12 108858932-108901043 Enzymes, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA038653, HPA038654 Supported Renal cancer:4.11e-4 (favourable) Tissue enriched Group enriched 36 kidney: 89.2;liver: 73.8 rectum: 2.2 DBH DBM ENSG00000123454 Dopamine beta-hydroxylase (dopamine beta-monooxygenase) 9 133636360-133659344 Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA002130, HPA005960, HPA070789 Supported Supported Vesicles Mixed Tissue enriched 12 adrenal gland: 358.5 epididymis: 30.6 DCXR DCR, KIDCR, SDR20C1 ENSG00000169738 Dicarbonyl/L-xylulose reductase 17 82035136-82037732 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA023371, HPA023863 Supported Uncertain Nucleoli
Microtubules Renal cancer:2.13e-4 (favourable), Pancreatic cancer:4.70e-4 (favourable) Expressed in all Group enriched 6 epididymis: 292.3;kidney: 216.4;liver: 638.6;prostate: 134.3 adipose tissue: 56.5 DDO ENSG00000203797 D-aspartate oxidase 6 110391771-110415562 Enzymes, Predicted membrane proteins Evidence at protein level HPA037525, HPA037526 Supported Supported Cytosol Renal cancer:8.69e-5 (favourable) Mixed Tissue enhanced parathyroid gland: 24.0 heart muscle: 11.7 DECR1 DECR, SDR18C1 ENSG00000104325 2,4-dienoyl CoA reductase 1, mitochondrial 8 90001405-90052092 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA023160, HPA023162, HPA023238 Supported Supported Mitochondria
Cytosol Renal cancer:1.79e-7 (favourable), Breast cancer:1.49e-4 (unfavourable), Urothelial cancer:6.06e-4 (favourable) Expressed in all Expressed in all liver: 262.7 DECR2 PDCR, SDR17C1 ENSG00000242612 2,4-dienoyl CoA reductase 2, peroxisomal 16 401826-412487 Enzymes, Predicted intracellular proteins Evidence at protein level HPA047631 Approved Peroxisomes Expressed in all Mixed duodenum: 10.8 DEGS1 DEGS-1, Des-1, DES1, FADS7, MLD ENSG00000143753 Delta(4)-desaturase, sphingolipid 1 1 224175756-224193441 Enzymes, Predicted membrane proteins Evidence at protein level HPA076422 Supported Mitochondria Renal cancer:6.83e-7 (unfavourable), Liver cancer:4.29e-5 (unfavourable), Endometrial cancer:7.74e-5 (unfavourable), Urothelial cancer:2.53e-4 (unfavourable) Expressed in all Expressed in all skin: 617.7 DEGS2 C14orf66, DES2, FADS8 ENSG00000168350 Delta(4)-desaturase, sphingolipid 2 14 100143957-100160163 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA046644 Approved Nucleus
Nucleoli Renal cancer:7.94e-7 (favourable), Urothelial cancer:1.66e-4 (favourable) Mixed Tissue enhanced skin: 31.3;small intestine: 39.5 duodenum: 25.5 DHCR24 DCE, KIAA0018, seladin-1 ENSG00000116133 24-dehydrocholesterol reductase 1 54849633-54887218 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB037247, HPA063005 Approved Endometrial cancer:1.05e-5 (unfavourable) Expressed in all Expressed in all adrenal gland: 1100.8 DHCR7 SLOS ENSG00000172893 7-dehydrocholesterol reductase 11 71428193-71452868 Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA044280 Approved Supported Endoplasmic reticulum
Cytosol Renal cancer:6.93e-7 (favourable), Urothelial cancer:5.67e-4 (unfavourable) Expressed in all Expressed in all adrenal gland: 116.0 DHDH HUM2DD ENSG00000104808 Dihydrodiol dehydrogenase (dimeric) 19 48933682-48944969 Enzymes, Predicted intracellular proteins Evidence at protein level HPA044131 Approved Approved Nucleoplasm
Actin filaments Renal cancer:3.15e-4 (favourable), Endometrial cancer:9.91e-4 (unfavourable) Expressed in all Tissue enhanced duodenum: 10.5;kidney: 17.8;small intestine: 19.0 prostate: 4.6 DHFR ENSG00000228716 Dihydrofolate reductase 5 80626228-80654983 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level CAB037129, HPA051465 Uncertain Supported Mitochondria Expressed in all Mixed lymph node: 50.1 DHFRL1 DHFRP4, FLJ16119 ENSG00000178700 Dihydrofolate reductase-like 1 3 94047836-94063389 Enzymes, Predicted intracellular proteins Evidence at protein level HPA051465 Uncertain Supported Mitochondria Renal cancer:2.30e-6 (favourable) Expressed in all Mixed parathyroid gland: 15.9 DHODH ENSG00000102967 Dihydroorotate dehydrogenase (quinone) 16 72008588-72027664 Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA010123, HPA011942 Approved Supported Nucleoplasm
Mitochondria Expressed in all Mixed liver: 23.7 DHRS3 RDH17, retSDR1, Rsdr1, SDR1, SDR16C1 ENSG00000162496 Dehydrogenase/reductase (SDR family) member 3 1 12567910-12617731 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA010844 Supported Approved Nucleoli
Mitochondria Thyroid cancer:2.65e-4 (favourable) Expressed in all Expressed in all adipose tissue: 99.6 DHRS4 FLJ11008, humNRDR, SCAD-SRL, SDR-SRL, SDR25C2 ENSG00000157326 Dehydrogenase/reductase (SDR family) member 4 14 23953586-23969279 Enzymes, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA023972 Uncertain Approved Nuclear membrane
Vesicles Renal cancer:4.55e-6 (favourable) Expressed in all Expressed in all kidney: 149.2 DHTKD1 CMT2Q, DKFZP762M115, KIAA1630, MGC3090 ENSG00000181192 Dehydrogenase E1 and transketolase domain containing 1 10 12068972-12123225 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA037949, HPA037950, HPA066098 Approved Supported Mitochondria Renal cancer:3.43e-4 (favourable) Expressed in all Expressed in all liver: 66.5 DIO2 SelY, TXDI2 ENSG00000211448 Deiodinase, iodothyronine, type II 14 80197527-80387757 Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA029544, HPA048002 Supported Nucleoplasm
Cytosol Endometrial cancer:4.62e-6 (favourable), Colorectal cancer:1.67e-4 (favourable) Tissue enhanced Group enriched 6 cervix, uterine: 268.3;thyroid gland: 599.1 esophagus: 70.6 DLD DLDH, GCSL, LAD ENSG00000091140 Dihydrolipoamide dehydrogenase 7 107890970-107931730 Citric acid cycle related proteins, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA044849 Supported Supported Mitochondria Renal cancer:7.58e-9 (favourable) Expressed in all Expressed in all kidney: 119.6 DMGDH ENSG00000132837 Dimethylglycine dehydrogenase 5 78997606-79236038 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA036441, HPA036442, HPA077849 Supported Uncertain Mitochondria Renal cancer:1.17e-5 (favourable), Liver cancer:5.32e-5 (favourable) Group enriched Group enriched 11 kidney: 177.8;liver: 146.1 epididymis: 14.7 DOHH HLRC1, MGC4293 ENSG00000129932 Deoxyhypusine hydroxylase/monooxygenase 19 3490821-3500940 Enzymes, Predicted intracellular proteins Evidence at protein level HPA041953 Approved Approved Nucleus
Cytosol Endometrial cancer:2.24e-4 (favourable), Pancreatic cancer:3.58e-4 (favourable) Expressed in all Mixed duodenum: 18.3 DPYD DPD ENSG00000188641 Dihydropyrimidine dehydrogenase 1 97077743-97921049 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level CAB033241, HPA045210 Uncertain Pancreatic cancer:6.27e-4 (unfavourable) Expressed in all Expressed in all lung: 44.1 DUOX1 LNOX1, NOXEF1, THOX1 ENSG00000137857 Dual oxidase 1 15 45129933-45165576 Enzymes, Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at protein level HPA023544 Approved Cervical cancer:4.31e-6 (favourable) Tissue enhanced Tissue enhanced skin: 96.8;thyroid gland: 92.3 esophagus: 73.4 EGLN1 C1orf12, HIFPH2, PHD2, SM-20, ZMYND6 ENSG00000135766 Egl-9 family hypoxia-inducible factor 1 1 231363751-231425044 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA022129 Approved Approved Cytosol Cervical cancer:2.99e-7 (unfavourable) Expressed in all Expressed in all parathyroid gland: 29.5 EGLN2 HIFPH1, PHD1 ENSG00000269858 Egl-9 family hypoxia-inducible factor 2 19 40798996-40808433 Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA056649 Supported Nucleoplasm Cervical cancer:2.88e-4 (favourable), Pancreatic cancer:4.81e-4 (favourable) Expressed in all Expressed in all testis: 205.0 EGLN3 HIFPH3, PHD3 ENSG00000129521 Egl-9 family hypoxia-inducible factor 3 14 33924231-34462774 Enzymes, Predicted intracellular proteins Evidence at protein level HPA064895 Approved Cytosol Liver cancer:2.14e-5 (unfavourable), Renal cancer:2.50e-4 (unfavourable) Expressed in all Tissue enhanced skin: 98.2 heart muscle: 58.6 EHHADH ECHD ENSG00000113790 Enoyl-CoA, hydratase/3-hydroxyacyl CoA dehydrogenase 3 185190624-185281990 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA036401, HPA042021 Supported Renal cancer:1.28e-5 (favourable) Group enriched Group enriched 7 kidney: 147.7;liver: 173.2 duodenum: 22.0 EPX EPO, EPP, EPX-PEN ENSG00000121053 Eosinophil peroxidase 17 58192737-58205174 Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins Evidence at protein level HPA050507 Approved Not detected Tissue enriched 14 bone marrow: 20.6 fallopian tube: 1.4 ETFDH ETFQO ENSG00000171503 Electron-transferring-flavoprotein dehydrogenase 4 158672125-158709623 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA041978 Supported Renal cancer:5.76e-10 (favourable) Expressed in all Expressed in all liver: 99.6 ETHE1 HSCO, YF13H12 ENSG00000105755 Ethylmalonic encephalopathy 1 19 43506719-43527244 Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA028360, HPA029028, HPA029029 Supported Validated Mitochondria Lung cancer:9.58e-4 (unfavourable) Expressed in all Expressed in all colon: 244.2 FADS2 D6D, DES6, FADSD6, LLCDL2, SLL0262, TU13 ENSG00000134824 Fatty acid desaturase 2 11 61792980-61867354 Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA006741 Approved Renal cancer:1.00e-7 (unfavourable), Urothelial cancer:3.42e-4 (unfavourable) Expressed in all Expressed in all adrenal gland: 416.6 FAM213B C1orf93, MGC26818 ENSG00000157870 Family with sequence similarity 213, member B 1 2586491-2591469 Enzymes, Predicted intracellular proteins Evidence at protein level HPA006403 Approved Approved Approved Nucleoplasm
Plasma membrane
Cytosol Renal cancer:1.28e-4 (favourable), Liver cancer:1.62e-4 (unfavourable) Expressed in all Mixed small intestine: 14.9 FAR1 FLJ22728, MLSTD2, SDR10E1 ENSG00000197601 Fatty acyl CoA reductase 1 11 13668670-13732346 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA017322 Approved Validated Peroxisomes Colorectal cancer:2.27e-4 (favourable) Expressed in all Expressed in all stomach: 59.0 FAR2 FLJ10462, MLSTD1, SDR10E2 ENSG00000064763 Fatty acyl CoA reductase 2 12 29149103-29340980 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA015884 Approved Approved Nucleoli
Golgi apparatus Renal cancer:4.93e-4 (unfavourable) Expressed in all Mixed epididymis: 52.9 FASN FAS, SDR27X1 ENSG00000169710 Fatty acid synthase 17 82078333-82098332 Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB005192, HPA006461, CAB015417, HPA056108 Supported Validated Plasma membrane
Cytosol Cervical cancer:1.42e-5 (unfavourable), Renal cancer:7.16e-5 (unfavourable) Expressed in all Expressed in all adipose tissue: 283.6 FDXR ADXR ENSG00000161513 Ferredoxin reductase 17 74862497-74873031 Enzymes, Predicted intracellular proteins Evidence at protein level CAB009818, HPA044393, HPA053673 Supported Validated Mitochondria Endometrial cancer:2.38e-4 (favourable) Expressed in all Tissue enriched 6 adrenal gland: 233.0 testis: 39.2 FMO1 ENSG00000010932 Flavin containing monooxygenase 1 1 171248471-171285978 Enzymes, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA023680 Uncertain Renal cancer:2.81e-4 (favourable) Tissue enriched Tissue enriched 8 kidney: 218.3 small intestine: 25.7 FMO2 ENSG00000094963 Flavin containing monooxygenase 2 (non-functional) 1 171185208-171211230 Enzymes, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA028261 Approved Mixed Tissue enhanced adipose tissue: 98.1;esophagus: 103.4;lung: 158.2 breast: 56.2 FMO3 ENSG00000007933 Flavin containing monooxygenase 3 1 171090877-171117819 Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA013750 Supported Lung cancer:5.60e-5 (favourable), Renal cancer:1.13e-4 (unfavourable), Liver cancer:3.46e-4 (favourable) Tissue enriched Tissue enriched 25 liver: 555.8 fallopian tube: 22.5 FMO4 FMO2 ENSG00000076258 Flavin containing monooxygenase 4 1 171314208-171342084 Enzymes, Predicted membrane proteins Evidence at protein level HPA049100 Uncertain Liver cancer:1.09e-4 (favourable), Renal cancer:6.96e-4 (favourable), Lung cancer:7.45e-4 (favourable) Expressed in all Tissue enhanced kidney: 47.7;liver: 30.1 parathyroid gland: 10.7 FMO5 ENSG00000131781 Flavin containing monooxygenase 5 1 147175351-147243050 Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA012373 Supported Supported Endoplasmic reticulum
Cytosol Renal cancer:1.34e-6 (favourable) Tissue enriched Tissue enhanced liver: 324.2 small intestine: 77.0 FTH1 FHC, FTH, FTHL6, PIG15, PLIF ENSG00000167996 Ferritin, heavy polypeptide 1 11 61959718-61967660 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB008623 Approved Approved Microtubules Renal cancer:5.20e-5 (unfavourable), Head and neck cancer:7.56e-5 (unfavourable), Liver cancer:6.18e-4 (unfavourable) Expressed in all Expressed in all appendix: 5085.0 FXN CyaY, FA, FARR, FRDA, X25 ENSG00000165060 Frataxin 9 69035259-69100178 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins, Transporters Evidence at protein level CAB022164, HPA068304 Supported Supported Mitochondria
Cytosol Expressed in all Expressed in all parathyroid gland: 33.5 G6PD G6PD1 ENSG00000160211 Glucose-6-phosphate dehydrogenase X 154531391-154547572 Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA000247, HPA000834 Supported Approved Vesicles
Microtubule organizing center
Cytosol Liver cancer:9.45e-13 (unfavourable) Expressed in all Expressed in all testis: 107.0 GAPDH GAPD ENSG00000111640 Glyceraldehyde-3-phosphate dehydrogenase 12 6533927-6538374 Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB005197, CAB016392, HPA040067, HPA061280 Supported Validated Plasma membrane
Cytosol Renal cancer:6.25e-10 (unfavourable), Liver cancer:1.79e-6 (unfavourable) Expressed in all Expressed in all skeletal muscle: 9875.4 GAPDHS GAPD2, GAPDH-2, GAPDS ENSG00000105679 Glyceraldehyde-3-phosphate dehydrogenase, spermatogenic 19 35533412-35545316 Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA042666 Approved Approved Nucleoplasm
Centrosome Tissue enriched Tissue enriched 12 testis: 243.7 thyroid gland: 20.6 GCDH ACAD5 ENSG00000105607 Glutaryl-CoA dehydrogenase 19 12891026-12914207 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA043252, HPA048492 Supported Supported Mitochondria Renal cancer:6.79e-8 (favourable), Liver cancer:7.28e-5 (favourable), Lung cancer:3.35e-4 (favourable) Expressed in all Expressed in all liver: 42.8 GFER ALR, ERV1, HERV1, HPO1, HPO2, HSS ENSG00000127554 Growth factor, augmenter of liver regeneration 16 1984207-1987749 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA041227, HPA063553 Approved Validated Mitochondria
Cytosol Renal cancer:4.06e-4 (favourable) Expressed in all Expressed in all small intestine: 51.0 GLDC GCSP, NKH ENSG00000178445 Glycine dehydrogenase (decarboxylating) 9 6532464-6645650 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA002318, HPA052887 Supported Supported Nucleus
Mitochondria Endometrial cancer:5.24e-5 (unfavourable), Renal cancer:3.50e-4 (favourable) Tissue enhanced Tissue enhanced kidney: 58.8;liver: 39.3;placenta: 46.9 cerebral cortex: 18.7 GLUD1 GDH, GLUD ENSG00000148672 Glutamate dehydrogenase 1 10 87050486-87094866 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins Evidence at protein level HPA042492, HPA044839, HPA061369 Approved Supported Mitochondria Renal cancer:1.44e-6 (favourable), Pancreatic cancer:1.76e-5 (unfavourable), Glioma:5.08e-4 (favourable) Expressed in all Expressed in all liver: 457.5 GLUD2 GLUDP1 ENSG00000182890 Glutamate dehydrogenase 2 X 121047588-121050080 Enzymes, Predicted intracellular proteins Evidence at protein level HPA042492, HPA044839, HPA061369 Uncertain Supported Mitochondria Renal cancer:1.98e-4 (favourable) Mixed Tissue enriched 11 testis: 46.3 epididymis: 4.0 GMPR ENSG00000137198 Guanosine monophosphate reductase 6 16238580-16295549 Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA000904, HPA021476 Uncertain Renal cancer:2.94e-5 (favourable), Ovarian cancer:2.06e-4 (favourable), Lung cancer:8.07e-4 (favourable) Expressed in all Expressed in all skeletal muscle: 105.8 GMPR2 ENSG00000100938 Guanosine monophosphate reductase 2 14 24232422-24239242 Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA000904, HPA067884, HPA068782 Uncertain Approved Nucleoplasm
Nucleoli Renal cancer:2.21e-5 (favourable) Expressed in all Expressed in all parathyroid gland: 217.9 GPD1 ENSG00000167588 Glycerol-3-phosphate dehydrogenase 1 (soluble) 12 50103819-50111319 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA044620 Supported Mixed Tissue enhanced adipose tissue: 635.1;skeletal muscle: 195.8 kidney: 147.2 GPD2 ENSG00000115159 Glycerol-3-phosphate dehydrogenase 2 (mitochondrial) 2 156435290-156613735 Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA008012, HPA045506 Supported Liver cancer:1.44e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 44.9 GPX1 ENSG00000233276 Glutathione peroxidase 1 3 49357176-49358600 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB011582, HPA044758 Approved Supported Cytosol Endometrial cancer:7.78e-4 (favourable) Expressed in all Expressed in all adipose tissue: 275.5 GPX2 GSHPX-GI ENSG00000176153 Glutathione peroxidase 2 14 64939152-64942905 Cancer-related genes, Enzymes, Predicted intracellular proteins Evidence at protein level HPA003545 Supported Approved Nucleoplasm
Cytosol Head and neck cancer:5.10e-4 (unfavourable) Mixed Tissue enhanced gallbladder: 699.5;rectum: 466.5 stomach: 338.1 GPX3 ENSG00000211445 Glutathione peroxidase 3 5 151020438-151028993 Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB069456 Uncertain Stomach cancer:1.65e-4 (unfavourable) Expressed in all Expressed in all kidney: 11584.2 GPX4 MCSP, PHGPx ENSG00000167468 Glutathione peroxidase 4 19 1103926-1106791 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB008630, HPA047224, HPA058546 Supported Supported Nucleoplasm
Mitochondria Endometrial cancer:1.84e-5 (favourable), Cervical cancer:7.18e-4 (favourable), Pancreatic cancer:7.72e-4 (favourable), Renal cancer:8.61e-4 (favourable) Expressed in all Expressed in all testis: 1137.7 GPX7 FLJ14777, GPX6, NPGPx ENSG00000116157 Glutathione peroxidase 7 1 52602372-52609051 Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins Evidence at protein level HPA025829 Approved Nucleoli Renal cancer:2.26e-5 (unfavourable) Expressed in all Expressed in all placenta: 41.7 GPX8 EPLA847, UNQ847 ENSG00000164294 Glutathione peroxidase 8 (putative) 5 55160118-55167071 Enzymes, Predicted intracellular proteins Evidence at protein level HPA036720, HPA036721 Supported Supported Actin filaments
Cytosol Renal cancer:5.13e-9 (unfavourable), Stomach cancer:7.96e-4 (unfavourable) Expressed in all Mixed cervix, uterine: 47.7 GRHPR GLXR, PH2 ENSG00000137106 Glyoxylate reductase/hydroxypyruvate reductase 9 37422666-37436990 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA022971 Approved Approved Nucleoplasm
Cytosol Renal cancer:5.39e-9 (favourable), Breast cancer:7.00e-5 (favourable) Expressed in all Expressed in all liver: 322.8 GSR ENSG00000104687 Glutathione reductase 8 30678061-30727926 Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA001538, CAB008632 Approved Supported Plasma membrane
Cytosol Liver cancer:3.26e-5 (unfavourable), Colorectal cancer:4.08e-5 (favourable), Renal cancer:1.80e-4 (favourable), Cervical cancer:3.37e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 77.8 GSTO1 GSTTLp28, P28 ENSG00000148834 Glutathione S-transferase omega 1 10 104235356-104267459 Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA037603, HPA037604 Supported Renal cancer:2.11e-4 (unfavourable), Breast cancer:6.95e-4 (favourable), Head and neck cancer:8.83e-4 (unfavourable) Expressed in all Expressed in all liver: 265.4 GSTO2 ENSG00000065621 Glutathione S-transferase omega 2 10 104268873-104304945 Enzymes, Predicted intracellular proteins Evidence at protein level HPA048141 Approved Approved Nucleus
Nucleoli Renal cancer:7.10e-7 (favourable) Mixed Mixed testis: 36.0 H6PD GDH ENSG00000049239 Hexose-6-phosphate dehydrogenase (glucose 1-dehydrogenase) 1 9234775-9271337 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins Evidence at protein level HPA004824, HPA005440 Approved Uncertain Cytosol Expressed in all Expressed in all ovary,skin: 42.7 HAAO ENSG00000162882 3-hydroxyanthranilate 3,4-dioxygenase 2 42767089-42792593 Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA036394, HPA042024 Supported Liver cancer:5.77e-4 (favourable) Group enriched Tissue enhanced liver: 151.8 small intestine: 46.4 HADH HADH1, HADHSC, SCHAD ENSG00000138796 Hydroxyacyl-CoA dehydrogenase 4 107989714-108035175 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA039588, HPA043888 Supported Supported Mitochondria Renal cancer:0.00e+0 (favourable) Expressed in all Expressed in all kidney: 188.7 HADHA GBP, LCEH, LCHAD, MTPA ENSG00000084754 Hydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA thiolase/enoyl-CoA hydratase (trifunctional protein), alpha subunit 2 26190635-26244726 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA015536, HPA056070 Approved Validated Mitochondria Renal cancer:3.68e-5 (favourable) Expressed in all Expressed in all duodenum: 241.8 HAO1 GOX, GOX1 ENSG00000101323 Hydroxyacid oxidase (glycolate oxidase) 1 20 7882981-7940474 Enzymes, Predicted intracellular proteins Evidence at protein level HPA049552 Supported Tissue enriched Tissue enriched 307 liver: 308.2 kidney: 1.0 HGD AKU, HGO ENSG00000113924 Homogentisate 1,2-dioxygenase 3 120628173-120682571 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA047374, HPA052359 Supported Approved Nucleus
Nucleoli Endometrial cancer:1.78e-4 (favourable) Tissue enhanced Tissue enhanced kidney: 174.2;liver: 322.8 gallbladder: 87.5 HIBADH NS5ATP1 ENSG00000106049 3-hydroxyisobutyrate dehydrogenase 7 27525442-27662995 Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA019522, HPA021002 Supported Renal cancer:5.56e-11 (favourable) Expressed in all Expressed in all kidney: 112.0 HIF1AN DKFZp762F1811, FIH1, FLJ20615, FLJ22027 ENSG00000166135 Hypoxia inducible factor 1, alpha subunit inhibitor 10 100529072-100559998 Enzymes, Predicted intracellular proteins Evidence at protein level HPA048742, HPA065302, CAB069903 Supported Supported Nucleoplasm
Cytosol Expressed in all Expressed in all testis: 25.7 HMGCR ENSG00000113161 3-hydroxy-3-methylglutaryl-CoA reductase 5 75336329-75362104 Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA008338, CAB016797 Approved Renal cancer:9.42e-6 (favourable) Expressed in all Expressed in all cerebral cortex: 87.8 HMOX1 bK286B10, HO-1 ENSG00000100292 Heme oxygenase 1 22 35380361-35394214 Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA000635, CAB017444 Supported Uncertain Golgi apparatus
Plasma membrane Liver cancer:1.59e-4 (unfavourable) Expressed in all Expressed in all spleen: 435.2 HMOX2 HO-2 ENSG00000103415 Heme oxygenase 2 16 4474690-4510347 Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB025464, HPA040611 Supported Approved Vesicles
Cytosol Renal cancer:8.98e-6 (favourable), Endometrial cancer:7.91e-4 (favourable) Expressed in all Expressed in all testis: 97.3 HPD 4-HPPD, 4HPPD, GLOD3, PPD ENSG00000158104 4-hydroxyphenylpyruvate dioxygenase 12 121839527-121863596 Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA038321, HPA038322 Supported Uncertain Nuclear speckles Tissue enriched Group enriched 85 kidney: 526.3;liver: 1290.5 testis: 10.6 HPGD SDR36C1 ENSG00000164120 Hydroxyprostaglandin dehydrogenase 15-(NAD) 4 174490177-174523154 Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA004919, HPA005679 Supported Supported Nucleoplasm
Cytosol Renal cancer:3.20e-4 (favourable) Tissue enhanced Tissue enhanced urinary bladder: 389.1 stomach: 183.4 HSD11B1 HSD11, HSD11B, SDR26C1 ENSG00000117594 Hydroxysteroid (11-beta) dehydrogenase 1 1 209686178-209734950 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA047729 Supported Renal cancer:1.97e-10 (unfavourable) Tissue enriched Group enriched 9 liver: 491.1;placenta: 104.6 ovary: 31.5 HSD17B1 EDH17B2, EDHB17, HSD17, MGC138140, SDR28C1 ENSG00000108786 Hydroxysteroid (17-beta) dehydrogenase 1 17 42549214-42555213 Enzymes, Predicted intracellular proteins Evidence at protein level HPA021032, HPA065296 Supported Supported Cytosol Mixed Tissue enriched 14 placenta: 98.3 cerebral cortex: 7.1 HSD17B10 17b-HSD10, ABAD, CAMR, ERAB, HADH2, MHBD, MRPP2, MRXS10, SDR5C1 ENSG00000072506 Hydroxysteroid (17-beta) dehydrogenase 10 X 53431258-53434373 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA001432 Approved Cervical cancer:2.80e-4 (favourable) Expressed in all Expressed in all liver: 126.2 HSD17B11 17-BETA-HSD11, 17-BETA-HSDXI, DHRS8, PAN1B, RetSDR2, SDR16C2 ENSG00000198189 Hydroxysteroid (17-beta) dehydrogenase 11 4 87336610-87391386 Enzymes, Predicted secreted proteins Evidence at protein level HPA021608 Approved Supported Lipid droplets Expressed in all Expressed in all small intestine: 301.2 HSD17B12 KAR, SDR12C1 ENSG00000149084 Hydroxysteroid (17-beta) dehydrogenase 12 11 43556436-43856617 Enzymes, Predicted membrane proteins Evidence at protein level HPA016427 Approved Renal cancer:2.10e-8 (favourable), Liver cancer:2.76e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 205.0 HSD17B2 HSD17, SDR9C2 ENSG00000086696 Hydroxysteroid (17-beta) dehydrogenase 2 16 82035004-82098534 Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA021826, HPA050235 Supported Approved Endoplasmic reticulum Urothelial cancer:3.83e-4 (favourable) Tissue enhanced Tissue enhanced duodenum: 443.2;placenta: 548.0 small intestine: 204.1 HSD17B3 SDR12C2 ENSG00000130948 Hydroxysteroid (17-beta) dehydrogenase 3 9 96235306-96302152 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA056833 Supported Approved Vesicles Mixed Tissue enriched 15 testis: 74.6 thyroid gland: 4.8 HSD17B4 DBP, MFE-2, SDR8C1 ENSG00000133835 Hydroxysteroid (17-beta) dehydrogenase 4 5 119452443-119637199 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA021302, HPA021311, HPA021479 Supported Validated Peroxisomes Renal cancer:6.31e-6 (favourable), Colorectal cancer:1.33e-4 (favourable) Expressed in all Expressed in all thyroid gland: 228.6 HSD17B6 HSE, RODH, SDR9C6 ENSG00000025423 Hydroxysteroid (17-beta) dehydrogenase 6 12 56752161-56787790 Enzymes, Predicted intracellular proteins Evidence at protein level HPA059141 Supported Approved Nucleus
Vesicles Liver cancer:6.32e-4 (favourable) Tissue enriched Tissue enriched 10 liver: 929.1 seminal vesicle: 94.8 HSD17B7 PRAP, SDR37C1 ENSG00000132196 Hydroxysteroid (17-beta) dehydrogenase 7 1 162790702-162812817 Enzymes, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA047496 Approved Renal cancer:8.47e-5 (unfavourable) Expressed in all Mixed liver: 17.2 HSD17B8 D6S2245E, FABGL, H2-KE6, HKE6, KE6, RING2, SDR30C1 ENSG00000204228 Hydroxysteroid (17-beta) dehydrogenase 8 6 33204642-33206831 Enzymes, Predicted intracellular proteins Evidence at protein level HPA042132 Supported Renal cancer:2.18e-12 (favourable), Liver cancer:1.90e-5 (favourable), Breast cancer:9.99e-4 (favourable) Expressed in all Mixed parathyroid gland: 9.7 HSD3B1 HSD3B, HSDB3, SDR11E1 ENSG00000203857 Hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 1 119507198-119515054 Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA043261, HPA043264, HPA044028 Supported Urothelial cancer:4.59e-5 (favourable) Tissue enhanced Tissue enriched 12 placenta: 110.1 small intestine: 8.9 HSD3B2 SDR11E2 ENSG00000203859 Hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 2 1 119414931-119423035 Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA043261, HPA043264, HPA044028 Supported Tissue enhanced Tissue enriched 436 adrenal gland: 2394.6 testis: 5.4 HSD3B7 C(27)-3BETA-HSD, SDR11E3 ENSG00000099377 Hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 7 16 30985207-30989152 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA050521, HPA060847 Uncertain Supported Lipid droplets Renal cancer:1.60e-6 (unfavourable), Colorectal cancer:5.95e-4 (unfavourable) Expressed in all Expressed in all liver: 21.9 IDH1 ENSG00000138413 Isocitrate dehydrogenase 1 (NADP+), soluble 2 208236227-208266074 Cancer-related genes, Citric acid cycle related proteins, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level CAB033218, HPA035248, HPA057936, CAB062556 Supported Approved Nuclear bodies
Cytosol Renal cancer:2.45e-5 (unfavourable), Liver cancer:6.93e-5 (unfavourable) Expressed in all Expressed in all prostate: 359.5 IDH2 ENSG00000182054 Isocitrate dehydrogenase 2 (NADP+), mitochondrial 15 90083045-90102504 Cancer-related genes, Citric acid cycle related proteins, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA007831 Supported Supported Mitochondria Cervical cancer:5.15e-5 (favourable) Expressed in all Expressed in all skeletal muscle: 450.2 IDH3A ENSG00000166411 Isocitrate dehydrogenase 3 (NAD+) alpha 15 78131498-78171949 Citric acid cycle related proteins, Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA041465, HPA062971 Supported Validated Mitochondria Renal cancer:6.49e-8 (favourable) Expressed in all Expressed in all cerebral cortex: 44.3 IDH3B RP46 ENSG00000101365 Isocitrate dehydrogenase 3 (NAD+) beta 20 2658395-2664219 Citric acid cycle related proteins, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA049387, HPA054180 Supported Validated Mitochondria Renal cancer:6.78e-8 (favourable), Liver cancer:1.59e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 98.7 IDH3G ENSG00000067829 Isocitrate dehydrogenase 3 (NAD+) gamma X 153785766-153794523 Citric acid cycle related proteins, Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA000425, HPA002017 Supported Validated Mitochondria Renal cancer:5.73e-6 (favourable) Expressed in all Expressed in all cerebral cortex: 65.1 IDO1 IDO, INDO ENSG00000131203 Indoleamine 2,3-dioxygenase 1 8 39902275-39928444 Cancer-related genes, Enzymes, Predicted intracellular proteins Evidence at protein level HPA023072, HPA023149, HPA027772 Supported Renal cancer:1.12e-7 (unfavourable), Ovarian cancer:3.32e-4 (favourable), Melanoma:5.27e-4 (favourable) Expressed in all Tissue enhanced placenta: 148.0 lymph node: 58.1 IL4I1 FIG1 ENSG00000104951 Interleukin 4 induced 1 19 49889654-49929539 Enzymes, Predicted secreted proteins Evidence at protein level HPA045598 Supported Renal cancer:1.23e-10 (unfavourable), Glioma:1.85e-4 (unfavourable) Expressed in all Tissue enhanced appendix: 25.3;testis: 31.9 lymph node: 10.6 IMPDH1 LCA11, RP10, sWSS2608 ENSG00000106348 IMP (inosine 5'-monophosphate) dehydrogenase 1 7 128392277-128410252 Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level HPA001400 Approved Supported Cytosol
Rods & Rings Renal cancer:1.78e-12 (unfavourable), Liver cancer:1.12e-7 (unfavourable), Urothelial cancer:3.72e-5 (unfavourable), Glioma:1.17e-4 (unfavourable), Cervical cancer:3.87e-4 (unfavourable) Expressed in all Expressed in all appendix: 47.2 IMPDH2 ENSG00000178035 IMP (inosine 5'-monophosphate) dehydrogenase 2 3 49024325-49029408 Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA001400, CAB020717 Approved Validated Cytosol
Rods & Rings Liver cancer:3.22e-4 (unfavourable) Expressed in all Expressed in all ovary: 421.1 IVD ACAD2 ENSG00000128928 Isovaleryl-CoA dehydrogenase 15 40405795-40435947 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA041391, HPA044250 Supported Validated Nucleoplasm
Mitochondria Renal cancer:2.91e-9 (favourable), Liver cancer:1.95e-5 (favourable) Expressed in all Expressed in all thyroid gland: 151.3 IYD C6orf71, DEHAL1, dJ422F24.1 ENSG00000009765 Iodotyrosine deiodinase 6 150368892-150405969 Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA059627 Supported Supported Plasma membrane Liver cancer:6.22e-4 (favourable) Tissue enriched Tissue enriched 28 thyroid gland: 792.4 kidney: 27.9 KDM2A CXXC8, DKFZP434M1735, FBL11, FBL7, FBXL11, FLJ00115, JHDM1A, KIAA1004, LILINA ENSG00000173120 Lysine (K)-specific demethylase 2A 11 67119269-67258087 Enzymes, Plasma proteins, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB012272, HPA044251 Supported Approved Nucleus Expressed in all Expressed in all testis: 59.8 KDM2B CXXC2, Fbl10, FBXL10, JHDM1B, PCCX2 ENSG00000089094 Lysine (K)-specific demethylase 2B 12 121429097-121581015 Enzymes, Predicted intracellular proteins Evidence at protein level HPA071257 Uncertain Nucleoplasm Head and neck cancer:6.74e-6 (favourable), Pancreatic cancer:8.64e-4 (favourable) Expressed in all Expressed in all lymph node: 36.3 KDM8 FLJ13798, JMJD5 ENSG00000155666 Lysine (K)-specific demethylase 8 16 27203495-27221768 Enzymes, Predicted intracellular proteins Evidence at protein level HPA026545 Uncertain Approved Nucleoplasm
Cytosol Pancreatic cancer:1.75e-4 (favourable) Expressed in all Tissue enhanced liver: 24.2 small intestine: 14.1 KDSR DHSR, FVT1, SDR35C1 ENSG00000119537 3-ketodihydrosphingosine reductase 18 63327726-63367510 Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB003673, HPA044884 Approved Renal cancer:9.53e-6 (favourable) Expressed in all Expressed in all cerebral cortex: 45.6 KMO ENSG00000117009 Kynurenine 3-monooxygenase (kynurenine 3-hydroxylase) 1 241532134-241595642 Enzymes, Predicted membrane proteins Evidence at protein level HPA031115, HPA056942 Supported Renal cancer:6.49e-8 (unfavourable) Mixed Tissue enhanced kidney: 31.3;liver: 46.5 spleen: 10.8 L2HGDH C14orf160, FLJ12618 ENSG00000087299 L-2-hydroxyglutarate dehydrogenase 14 50237563-50312548 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA065409, HPA069708 Approved Validated Mitochondria Renal cancer:9.75e-10 (favourable) Expressed in all Mixed kidney: 20.7 LDHA ENSG00000134333 Lactate dehydrogenase A 11 18394388-18408425 Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level CAB015336 Approved Supported Vesicles
Cytosol Renal cancer:9.69e-9 (unfavourable), Liver cancer:3.26e-8 (unfavourable), Lung cancer:2.27e-6 (unfavourable), Pancreatic cancer:8.09e-6 (unfavourable), Cervical cancer:2.78e-5 (unfavourable) Expressed in all Expressed in all adipose tissue: 499.8 LDHAL6B LDH6B, LDHAL6, LDHL ENSG00000171989 Lactate dehydrogenase A-like 6B 15 59206823-59208515 Enzymes, Predicted intracellular proteins Evidence at protein level HPA053962 Supported Not detected Tissue enriched 165 testis: 76.1 gallbladder: 0.4 LDHB ENSG00000111716 Lactate dehydrogenase B 12 21635342-21757857 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level CAB004641, HPA019007 Supported Validated Cytosol Renal cancer:2.51e-4 (favourable) Expressed in all Expressed in all kidney: 1776.6 LDHC CT32 ENSG00000166796 Lactate dehydrogenase C 11 18412307-18452058 Enzymes, Predicted intracellular proteins Evidence at protein level HPA045442 Supported Mixed Tissue enriched 385 testis: 469.8 thyroid gland: 1.2 LDHD ENSG00000166816 Lactate dehydrogenase D 16 75111860-75116771 Enzymes, Predicted intracellular proteins Evidence at protein level HPA041766, HPA048639, HPA066148 Approved Approved Cytosol Renal cancer:2.95e-14 (favourable), Liver cancer:5.61e-4 (favourable) Expressed in all Mixed kidney: 33.9 LOX ENSG00000113083 Lysyl oxidase 5 122063195-122078285 Enzymes, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA043930 Supported Endoplasmic reticulum Renal cancer:3.93e-8 (unfavourable), Urothelial cancer:3.32e-4 (unfavourable), Liver cancer:7.38e-4 (unfavourable) Expressed in all Mixed adipose tissue: 28.4 LOXL2 WS9-14 ENSG00000134013 Lysyl oxidase-like 2 8 23297189-23425328 Enzymes, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB025848, HPA036257, HPA056542 Approved Approved Nucleoplasm Lung cancer:1.46e-7 (unfavourable), Renal cancer:2.91e-7 (unfavourable), Cervical cancer:9.83e-6 (unfavourable), Glioma:1.78e-4 (unfavourable), Pancreatic cancer:9.05e-4 (unfavourable) Expressed in all Tissue enhanced smooth muscle: 58.8 placenta: 53.0 LPO SPO ENSG00000167419 Lactoperoxidase 17 58218548-58268518 Enzymes, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA028688 Supported Not detected Tissue enriched 219 salivary gland: 374.4 testis: 1.7 MAOA ENSG00000189221 Monoamine oxidase A X 43654907-43746824 Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins Evidence at protein level CAB009437, HPA054807, HPA059299 Supported Validated Mitochondria Expressed in all Mixed small intestine: 253.2 MAOB ENSG00000069535 Monoamine oxidase B X 43766611-43882447 Enzymes, FDA approved drug targets, Predicted membrane proteins Evidence at protein level HPA002328, CAB037200 Supported Approved Nucleoli
Mitochondria Expressed in all Mixed seminal vesicle: 213.0 MDH1 ENSG00000014641 Malate dehydrogenase 1, NAD (soluble) 2 63588609-63607197 Cancer-related genes, Citric acid cycle related proteins, Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA027296, CAB047333, HPA054276 Uncertain Supported Centrosome
Cytosol Endometrial cancer:7.13e-4 (unfavourable), Renal cancer:9.95e-4 (favourable) Expressed in all Expressed in all heart muscle: 736.3 MDH2 ENSG00000146701 Malate dehydrogenase 2, NAD (mitochondrial) 7 76048051-76067508 Citric acid cycle related proteins, Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA019714, HPA019716, HPA019848, HPA026720 Supported Validated Mitochondria Renal cancer:1.49e-5 (favourable) Expressed in all Expressed in all skeletal muscle: 233.3 ME1 ENSG00000065833 Malic enzyme 1, NADP(+)-dependent, cytosolic 6 83210389-83431071 Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA006493 Approved Approved Nucleoplasm
Plasma membrane
Cytosol Renal cancer:1.81e-7 (unfavourable), Liver cancer:4.57e-5 (unfavourable) Expressed in all Mixed parathyroid gland: 53.1 ME2 ENSG00000082212 Malic enzyme 2, NAD(+)-dependent, mitochondrial 18 50879049-50954257 Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA008247, HPA008880 Supported Validated Mitochondria Liver cancer:8.29e-8 (unfavourable) Expressed in all Expressed in all spleen: 54.3 ME3 ENSG00000151376 Malic enzyme 3, NADP(+)-dependent, mitochondrial 11 86441108-86672636 Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA038473 Approved Urothelial cancer:3.86e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 39.0 MECR CGI-63, FASN2B, NRBF1 ENSG00000116353 Mitochondrial trans-2-enoyl-CoA reductase 1 29192873-29230942 Enzymes, Predicted intracellular proteins Evidence at protein level HPA022018, HPA022030, HPA028740 Supported Supported Mitochondria Renal cancer:5.81e-6 (favourable), Urothelial cancer:5.29e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 18.4 MIOX ALDRL6 ENSG00000100253 Myo-inositol oxygenase 22 50486784-50490648 Enzymes, Predicted intracellular proteins Evidence at protein level HPA039451, HPA039562 Supported Renal cancer:2.60e-6 (favourable) Tissue enriched Tissue enriched 30 kidney: 818.9 thyroid gland: 26.8 MPO ENSG00000005381 Myeloperoxidase 17 58269856-58280935 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB000059, HPA021147, HPA061464 Supported Supported Nucleus
Vesicles Tissue enhanced Tissue enriched 81 bone marrow: 2504.1 salivary gland: 30.8 MSMO1 DESP4, ERG25, SC4MOL ENSG00000052802 Methylsterol monooxygenase 1 4 165327623-165343160 Enzymes, Predicted membrane proteins Evidence at protein level HPA056127 Approved Cervical cancer:2.97e-4 (unfavourable), Renal cancer:9.21e-4 (favourable) Expressed in all Expressed in all liver: 296.4 MSRA ENSG00000175806 Methionine sulfoxide reductase A 8 10054268-10428891 Enzymes, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA023804, HPA053069 Approved Validated Nucleoplasm
Cytosol Expressed in all Expressed in all kidney: 112.4 MT-CO1 COI, COX1, MTCO1 ENSG00000198804 Mitochondrially encoded cytochrome c oxidase I MT 5904-7445 Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level CAB016241, HPA069328 Supported Supported Mitochondria Liver cancer:2.29e-4 (favourable) Expressed in all Expressed in all heart muscle: 79793.3 MT-ND1 MTND1, NAD1, ND1 ENSG00000198888 Mitochondrially encoded NADH dehydrogenase 1 MT 3307-4262 Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins Evidence at protein level CAB033779 Approved Pancreatic cancer:3.26e-4 (favourable), Breast cancer:3.63e-4 (favourable) Expressed in all Expressed in all skeletal muscle: 23823.0 MT-ND3 MTND3, NAD3, ND3 ENSG00000198840 Mitochondrially encoded NADH dehydrogenase 3 MT 10059-10404 Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA063296 Supported Approved Cytosol Liver cancer:4.63e-5 (favourable) Expressed in all Expressed in all heart muscle: 30137.8 MT-ND4 LHON, MTND4, NAD4, ND4 ENSG00000198886 Mitochondrially encoded NADH dehydrogenase 4 MT 10760-12137 Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA053928 Approved Ovarian cancer:1.76e-4 (favourable) Expressed in all Expressed in all heart muscle: 38133.1 MT-ND4L MTND4L, NAD4L, ND4L ENSG00000212907 Mitochondrially encoded NADH dehydrogenase 4L MT 10470-10766 Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA075648 Approved Mitochondria Liver cancer:4.47e-4 (favourable) Expressed in all Expressed in all heart muscle: 23512.4 MTHFD1 MTHFC, MTHFD ENSG00000100714 Methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 1, methenyltetrahydrofolate cyclohydrolase, formyltetrahydrofolate synthetase 14 64388031-64463457 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA000704, HPA001290, HPA015006, HPA050052 Approved Validated Cytosol Renal cancer:5.93e-5 (favourable), Pancreatic cancer:6.96e-4 (unfavourable) Expressed in all Expressed in all liver: 198.3 MTHFD2 ENSG00000065911 Methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2, methenyltetrahydrofolate cyclohydrolase 2 74198562-74217565 Enzymes, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB003684, HPA049657 Approved Renal cancer:1.11e-16 (unfavourable), Endometrial cancer:2.07e-5 (unfavourable), Glioma:8.47e-5 (favourable) Expressed in all Expressed in all appendix: 40.7 MTHFD2L MGC72244 ENSG00000163738 Methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2-like 4 74114174-74303099 Enzymes, Predicted intracellular proteins Evidence at protein level HPA035434 Uncertain Mixed Mixed adrenal gland: 4.9 MTHFR ENSG00000177000 Methylenetetrahydrofolate reductase (NAD(P)H) 1 11785723-11806920 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA063389 Approved Cell Junctions Head and neck cancer:3.97e-5 (favourable), Pancreatic cancer:4.81e-5 (favourable), Liver cancer:1.19e-4 (unfavourable), Renal cancer:2.12e-4 (favourable) Expressed in all Expressed in all epididymis: 65.3 MTRR cblE ENSG00000124275 5-methyltetrahydrofolate-homocysteine methyltransferase reductase 5 7851186-7906025 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA038113 Supported Approved Nucleoplasm
Intermediate filaments
Cytosol Liver cancer:6.60e-4 (unfavourable) Expressed in all Expressed in all kidney: 20.4 NDUFS1 CI-75k ENSG00000023228 NADH dehydrogenase (ubiquinone) Fe-S protein 1, 75kDa (NADH-coenzyme Q reductase) 2 206114817-206159603 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA064605, CAB070844 Approved Supported Mitochondria Renal cancer:1.47e-12 (favourable), Breast cancer:3.85e-4 (unfavourable) Expressed in all Expressed in all heart muscle: 141.0 NDUFS2 CI-49 ENSG00000158864 NADH dehydrogenase (ubiquinone) Fe-S protein 2, 49kDa (NADH-coenzyme Q reductase) 1 161197104-161214395 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA055140, HPA061953 Supported Validated Nucleoplasm
Mitochondria Renal cancer:2.32e-4 (favourable) Expressed in all Expressed in all heart muscle: 126.4 NDUFS3 CI-30 ENSG00000213619 NADH dehydrogenase (ubiquinone) Fe-S protein 3, 30kDa (NADH-coenzyme Q reductase) 11 47565336-47584562 Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA004484 Approved Supported Nuclear bodies
Mitochondria Renal cancer:2.61e-6 (favourable) Expressed in all Expressed in all skeletal muscle: 127.3 NDUFS8 CI-23k, TYKY ENSG00000110717 NADH dehydrogenase (ubiquinone) Fe-S protein 8, 23kDa (NADH-coenzyme Q reductase) 11 68030617-68036644 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA018524 Approved Supported Mitochondria Renal cancer:3.27e-8 (favourable) Expressed in all Expressed in all adrenal gland: 153.3 NDUFV1 CI-51K ENSG00000167792 NADH dehydrogenase (ubiquinone) flavoprotein 1, 51kDa 11 67606852-67612535 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA045211, HPA075051 Approved Supported Mitochondria
Cytosol Renal cancer:7.49e-10 (favourable) Expressed in all Expressed in all parathyroid gland: 218.0 NDUFV2 CI-24k ENSG00000178127 NADH dehydrogenase (ubiquinone) flavoprotein 2, 24kDa 18 9102630-9134345 Enzymes, Predicted intracellular proteins Evidence at protein level HPA003404, HPA077896 Supported Approved Supported Mitochondria Expressed in all Expressed in all skeletal muscle: 190.9 NNT ENSG00000112992 Nicotinamide nucleotide transhydrogenase 5 43602692-43707405 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA004829, CAB004975 Supported Validated Mitochondria Renal cancer:1.22e-15 (favourable) Expressed in all Expressed in all heart muscle: 139.6 NOS1 nNOS, NOS ENSG00000089250 Nitric oxide synthase 1 (neuronal) 12 117208142-117452170 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB002167, HPA058312 Uncertain Supported Nucleoplasm
Plasma membrane Mixed Tissue enhanced skeletal muscle: 12.9 cerebral cortex: 3.0 NOS2 HEP-NOS, iNOS, NOS, NOS2A ENSG00000007171 Nitric oxide synthase 2, inducible 17 27756766-27800499 Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB002014 Approved Tissue enhanced Group enriched 5 appendix: 19.6;colon: 7.2;duodenum: 12.6;rectum: 10.0;small intestine: 24.6;urinary bladder: 6.7 smooth muscle: 2.5 NOS3 ECNOS, eNOS ENSG00000164867 Nitric oxide synthase 3 (endothelial cell) 7 150990995-151014588 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB002168 Supported Renal cancer:3.63e-4 (unfavourable) Expressed in all Tissue enriched 7 spleen: 73.1 adipose tissue: 10.7 NQO1 DHQU, DIA4, DTD, NMOR1, QR1 ENSG00000181019 NAD(P)H dehydrogenase, quinone 1 16 69706996-69726951 Cancer-related genes, Enzymes, Predicted intracellular proteins Evidence at protein level HPA007308, CAB012421 Supported Validated Cytosol Head and neck cancer:1.45e-4 (unfavourable) Expressed in all Tissue enhanced breast: 371.7;stomach: 559.0 gallbladder: 321.6 NQO2 DHQV, DIA6, NMOR2, QR2 ENSG00000124588 NAD(P)H dehydrogenase, quinone 2 6 2987987-3028869 Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA021283, HPA021332 Supported Supported Nucleoplasm
Cytosol Liver cancer:8.40e-4 (unfavourable) Expressed in all Expressed in all kidney: 201.3 NSDHL H105e3, SDR31E1, XAP104 ENSG00000147383 NAD(P) dependent steroid dehydrogenase-like X 152830967-152869729 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA000248, HPA000571 Supported Validated Endoplasmic reticulum
Lipid droplets Renal cancer:6.09e-5 (favourable), Liver cancer:5.04e-4 (unfavourable), Cervical cancer:5.65e-4 (favourable) Expressed in all Expressed in all epididymis: 53.2 NXN FLJ12614, NRX ENSG00000167693 Nucleoredoxin 17 799313-979770 Enzymes, Predicted intracellular proteins Evidence at protein level HPA023566 Approved Supported Golgi apparatus
Cytosol Expressed in all Mixed endometrium: 42.6 OGDH E1k ENSG00000105953 Oxoglutarate (alpha-ketoglutarate) dehydrogenase (lipoamide) 7 44606572-44709066 Citric acid cycle related proteins, Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA019514, HPA020347 Supported Validated Mitochondria Renal cancer:2.22e-14 (favourable) Expressed in all Expressed in all heart muscle: 146.5 P3H1 GROS1, LEPRE1, LEPRECAN, MGC117314 ENSG00000117385 Prolyl 3-hydroxylase 1 1 42746335-42767084 Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins Evidence at protein level HPA012113, HPA016980 Approved Approved Nucleoli
Vesicles Renal cancer:0.00e+0 (unfavourable), Liver cancer:4.95e-7 (unfavourable) Expressed in all Tissue enhanced placenta: 53.1 smooth muscle: 28.0 P3H2 FLJ10718, LEPREL1, MLAT4 ENSG00000090530 Prolyl 3-hydroxylase 2 3 189956728-190122437 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA007890, HPA013355 Approved Expressed in all Mixed prostate: 68.1 P3H3 GRCB, HSU47926, LEPREL2 ENSG00000110811 Prolyl 3-hydroxylase 3 12 6828410-6839851 Enzymes, Predicted secreted proteins Evidence at protein level HPA043695 Approved Renal cancer:1.64e-4 (unfavourable), Pancreatic cancer:4.91e-4 (favourable) Expressed in all Tissue enhanced parathyroid gland: 11.5 endometrium: 6.2 P4HA1 C-P4Halpha(I), P4HA ENSG00000122884 Prolyl 4-hydroxylase, alpha polypeptide I 10 73007217-73096974 Enzymes, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA007599, HPA026593 Supported Supported Endoplasmic reticulum
Vesicles
Mitochondria Renal cancer:9.40e-9 (unfavourable), Head and neck cancer:1.19e-5 (unfavourable), Cervical cancer:3.19e-5 (unfavourable), Pancreatic cancer:2.85e-4 (unfavourable), Lung cancer:5.10e-4 (unfavourable), Breast cancer:9.01e-4 (unfavourable) Expressed in all Expressed in all placenta: 91.1 P4HA2 C-P4Halpha(II) ENSG00000072682 Prolyl 4-hydroxylase, alpha polypeptide II 5 132191838-132295315 Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins Evidence at protein level HPA016997, HPA027824, CAB062557 Supported Validated Endoplasmic reticulum
Vesicles Renal cancer:2.77e-7 (unfavourable), Cervical cancer:1.24e-5 (unfavourable), Urothelial cancer:3.12e-4 (unfavourable) Expressed in all Expressed in all epididymis: 93.7 P4HA3 C-P4Halpha(III) ENSG00000149380 Prolyl 4-hydroxylase, alpha polypeptide III 11 74235801-74311657 Enzymes, Predicted secreted proteins Evidence at protein level HPA007897 Supported Renal cancer:3.34e-9 (unfavourable), Urothelial cancer:7.83e-4 (unfavourable) Mixed Tissue enhanced smooth muscle: 14.2 urinary bladder: 9.0 PAH PH ENSG00000171759 Phenylalanine hydroxylase 12 102836885-102958410 Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level HPA028407, HPA031642 Supported Approved Endoplasmic reticulum
Vesicles Liver cancer:4.30e-4 (favourable) Tissue enriched Tissue enhanced kidney: 500.3;liver: 720.9 gallbladder: 126.2 PAM PAL, PHM ENSG00000145730 Peptidylglycine alpha-amidating monooxygenase 5 102753981-103031105 Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB026119, HPA042260 Supported Approved Golgi apparatus
Cytosol Endometrial cancer:1.63e-4 (favourable), Liver cancer:6.20e-4 (unfavourable) Expressed in all Expressed in all heart muscle: 1092.7 PAOX PAO ENSG00000148832 Polyamine oxidase (exo-N4-amino) 10 133379234-133391694 Enzymes, Predicted intracellular proteins Evidence at protein level HPA047782 Uncertain Nucleoplasm
Centrosome Head and neck cancer:1.38e-5 (favourable), Cervical cancer:6.07e-5 (favourable), Renal cancer:9.49e-4 (favourable) Expressed in all Tissue enhanced testis: 7.6 cerebral cortex: 3.2 PCYOX1 KIAA0908, PCL1 ENSG00000116005 Prenylcysteine oxidase 1 2 70257386-70281191 Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA035193 Approved Renal cancer:1.89e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 138.9 PDHA1 PDHA ENSG00000131828 Pyruvate dehydrogenase (lipoamide) alpha 1 X 19343893-19361705 Citric acid cycle related proteins, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA047487, HPA047864, HPA063053 Approved Supported Mitochondria Renal cancer:1.13e-7 (favourable) Expressed in all Expressed in all heart muscle: 231.0 PDHA2 PDHAL ENSG00000163114 Pyruvate dehydrogenase (lipoamide) alpha 2 4 95840019-95841474 Citric acid cycle related proteins, Enzymes, Predicted intracellular proteins Evidence at protein level HPA047487, HPA047864, HPA063053 Approved Supported Mitochondria Not detected Tissue enriched 1006 testis: 100.5 all non-specific tissues: 0.0 PDHB ENSG00000168291 Pyruvate dehydrogenase (lipoamide) beta 3 58427630-58433857 Citric acid cycle related proteins, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level CAB033794, HPA036744, HPA036745 Supported Supported Nucleoplasm
Mitochondria Renal cancer:2.79e-8 (favourable) Expressed in all Expressed in all heart muscle: 111.5 PECR HSA250303, SDR29C1, TERP ENSG00000115425 Peroxisomal trans-2-enoyl-CoA reductase 2 215996329-216082955 Enzymes, Predicted intracellular proteins Evidence at protein level HPA021593, HPA022539 Approved Supported Peroxisomes Renal cancer:1.36e-5 (favourable) Expressed in all Expressed in all liver: 82.9 PGD ENSG00000142657 Phosphogluconate dehydrogenase 1 10398592-10420144 Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA031314, HPA031315 Approved Supported Approved Intermediate filaments
Cytosol Liver cancer:3.98e-4 (unfavourable) Expressed in all Expressed in all esophagus: 488.7 PHF8 JHDM1F, KIAA1111, ZNF422 ENSG00000172943 PHD finger protein 8 X 53936676-54048958 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA038779, HPA062015 Approved Supported Nucleus Urothelial cancer:3.74e-5 (favourable) Expressed in all Expressed in all epididymis: 84.6 PHGDH PDG, PGDH, SERA ENSG00000092621 Phosphoglycerate dehydrogenase 1 119659798-119744215 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level CAB003681, HPA021241, HPA024031, CAB068216 Supported Validated Nucleoplasm
Plasma membrane
Cytosol Endometrial cancer:1.48e-4 (unfavourable), Glioma:2.26e-4 (favourable) Expressed in all Tissue enhanced parathyroid gland: 212.4 skin: 116.1 PHYH PAHX, PHYH1, RD ENSG00000107537 Phytanoyl-CoA 2-hydroxylase 10 13277796-13302412 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA007598, HPA011796 Approved Renal cancer:7.28e-12 (favourable) Expressed in all Expressed in all liver: 333.3 PIR ENSG00000087842 Pirin (iron-binding nuclear protein) X 15384799-15493564 Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA000697 Approved Supported Cytosol Renal cancer:6.11e-7 (unfavourable), Cervical cancer:2.78e-4 (favourable), Ovarian cancer:4.94e-4 (favourable) Expressed in all Mixed urinary bladder: 23.4 PLOD1 LH1, LLH, PLOD ENSG00000083444 Procollagen-lysine, 2-oxoglutarate 5-dioxygenase 1 1 11934205-11975538 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins Evidence at protein level HPA049137, HPA055799 Uncertain Uncertain Nucleoplasm
Vesicles Renal cancer:1.91e-12 (unfavourable), Urothelial cancer:2.43e-4 (unfavourable), Liver cancer:2.79e-4 (unfavourable) Expressed in all Expressed in all placenta: 121.3 PLOD2 LH2 ENSG00000152952 Procollagen-lysine, 2-oxoglutarate 5-dioxygenase 2 3 146069440-146163653 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB025898, HPA069126 Approved Uncertain Nucleoli
Cytosol Renal cancer:4.99e-11 (unfavourable), Liver cancer:7.64e-10 (unfavourable), Lung cancer:1.42e-4 (unfavourable), Cervical cancer:1.97e-4 (unfavourable), Stomach cancer:2.83e-4 (unfavourable) Expressed in all Mixed thyroid gland: 150.3 PLOD3 LH3 ENSG00000106397 Procollagen-lysine, 2-oxoglutarate 5-dioxygenase 3 7 101205977-101218420 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA001236 Uncertain Cervical cancer:1.91e-5 (unfavourable), Colorectal cancer:3.26e-4 (unfavourable) Expressed in all Expressed in all placenta: 48.0 PNPO PDXPO ENSG00000108439 Pyridoxamine 5'-phosphate oxidase 17 47941506-47948288 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA023204, HPA027776 Approved Supported Nucleoplasm
Cytosol Expressed in all Expressed in all liver: 51.2 POR CYPOR, FLJ26468 ENSG00000127948 P450 (cytochrome) oxidoreductase 7 75899200-75986855 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB004372, HPA010136 Supported Approved Nucleoplasm
Vesicles
Cytosol Glioma:5.23e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 219.8 PPOX PPO, VP ENSG00000143224 Protoporphyrinogen oxidase 1 161166410-161178013 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA030123 Uncertain Approved Mitochondria
Cytosol Renal cancer:9.89e-4 (unfavourable) Expressed in all Expressed in all fallopian tube: 37.3 PRDX1 NKEFA, PAGA ENSG00000117450 Peroxiredoxin 1 1 45511036-45523047 Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB004682, HPA007730 Approved Supported Mitochondria Liver cancer:1.17e-5 (unfavourable), Urothelial cancer:2.89e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 1203.6 PRDX2 MGC4104, NKEFB, PRP, PRX2, PRXII, TDPX1, TSA ENSG00000167815 Peroxiredoxin 2 19 12796820-12801859 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB008713 Approved Renal cancer:5.66e-11 (favourable) Expressed in all Expressed in all adrenal gland: 471.1 PRDX3 AOP-1, AOP1, MER5, SP-22 ENSG00000165672 Peroxiredoxin 3 10 119167703-119178833 Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB008656, HPA041488 Supported Expressed in all Expressed in all adrenal gland: 431.2 PRDX4 AOE37-2 ENSG00000123131 Peroxiredoxin 4 X 23664262-23686399 Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB008659, CAB027389, CAB047362 Supported Supported Endoplasmic reticulum
Cytosol Renal cancer:1.33e-6 (unfavourable) Expressed in all Expressed in all pancreas: 239.4 PRDX5 ACR1, AOEB166, B166, MGC117264, MGC142283, MGC142285, PLP, PMP20, PRDX6, PRXV, SBBI10 ENSG00000126432 Peroxiredoxin 5 11 64318088-64321811 Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB008661, HPA037915, HPA037916 Supported Validated Mitochondria
Cytosol Renal cancer:1.24e-5 (favourable) Expressed in all Expressed in all fallopian tube: 599.3 PRDX6 1-Cys, aiPLA2, AOP2, KIAA0106, MGC46173, NSGPx, p29, PRX ENSG00000117592 Peroxiredoxin 6 1 173477266-173488807 Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA006983, CAB008663 Supported Supported Plasma membrane
Cytosol Head and neck cancer:1.23e-5 (unfavourable), Renal cancer:9.51e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 363.4 PRODH HSPOX2, PIG6, PRODH1, PRODH2, TP53I6 ENSG00000100033 Proline dehydrogenase (oxidase) 1 22 18912777-18936553 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA020361 Uncertain Cervical cancer:1.54e-4 (favourable) Tissue enhanced Tissue enhanced small intestine: 25.8 duodenum: 5.9 PRODH2 HSPOX1 ENSG00000250799 Proline dehydrogenase (oxidase) 2 19 35799988-35813299 Enzymes, Predicted intracellular proteins Evidence at protein level HPA051287 Approved Supported Nucleoplasm
Cytosol Group enriched Group enriched 94 kidney: 132.6;liver: 45.0 testis: 0.9 PTGR1 LTB4DH, ZADH3 ENSG00000106853 Prostaglandin reductase 1 9 111549722-111599855 Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA036724 Supported Renal cancer:5.53e-4 (favourable) Expressed in all Expressed in all small intestine: 321.1 PTGR2 FLJ39091, ZADH1 ENSG00000140043 Prostaglandin reductase 2 14 73851844-73886827 Enzymes, Predicted intracellular proteins Evidence at protein level HPA001125 Approved Approved Vesicles Renal cancer:4.55e-12 (favourable) Expressed in all Mixed thyroid gland: 21.3 PTGS1 COX1, PGHS-1, PTGHS ENSG00000095303 Prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase) 9 122370530-122395703 Cancer-related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA002834, CAB020315 Supported Supported Golgi apparatus
Vesicles Renal cancer:8.68e-4 (unfavourable), Urothelial cancer:9.35e-4 (unfavourable) Expressed in all Tissue enhanced skin: 161.9 esophagus: 85.8 PTGS2 COX2 ENSG00000073756 Prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) 1 186671791-186680427 Cancer-related genes, Enzymes, FDA approved drug targets, Predicted secreted proteins Evidence at protein level CAB000113, HPA001335 Approved Supported Endoplasmic reticulum Renal cancer:9.79e-4 (unfavourable) Mixed Tissue enhanced seminal vesicle: 178.8 cervix, uterine: 98.8 PXDN D2S448, D2S448E, KIAA0230, MG50, PRG2, PXN ENSG00000130508 Peroxidasin 2 1631887-1744852 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA012375 Approved Endometrial cancer:2.75e-4 (unfavourable), Cervical cancer:6.28e-4 (unfavourable), Stomach cancer:6.73e-4 (unfavourable) Expressed in all Tissue enhanced smooth muscle: 86.1 adipose tissue: 66.6 PXDNL FLJ25471, PMR1 ENSG00000147485 Peroxidasin-like 8 51319578-51809445 Enzymes, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA007919 Approved Nucleoplasm
Cytosol Breast cancer:3.27e-5 (unfavourable) Mixed Group enriched 8 epididymis: 11.3;heart muscle: 24.9;testis: 9.0 adipose tissue: 1.8 PYCR1 P5C ENSG00000183010 Pyrroline-5-carboxylate reductase 1 17 81932384-81942412 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA047660 Approved Renal cancer:7.33e-12 (unfavourable), Liver cancer:2.33e-4 (unfavourable) Expressed in all Mixed salivary gland: 52.6 PYCR2 P5CR2 ENSG00000143811 Pyrroline-5-carboxylate reductase family, member 2 1 225919877-225924340 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA056873 Approved Approved Mitochondria Renal cancer:1.42e-6 (unfavourable), Colorectal cancer:5.02e-5 (unfavourable) Expressed in all Expressed in all fallopian tube: 71.0 PYCRL FLJ13852 ENSG00000104524 Pyrroline-5-carboxylate reductase-like 8 143603913-143609773 Enzymes, Predicted intracellular proteins Evidence at protein level HPA063416, HPA069706 Uncertain Approved Nucleoplasm
Cytosol Expressed in all Mixed cerebral cortex: 4.1 QDPR DHPR, PKU2, SDR33C1 ENSG00000151552 Quinoid dihydropteridine reductase 4 17460261-17512234 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA058951, HPA065649 Supported Approved Mitochondria Renal cancer:7.84e-6 (favourable) Expressed in all Expressed in all cerebral cortex: 226.9 QSOX1 QSCN6 ENSG00000116260 Quiescin Q6 sulfhydryl oxidase 1 1 180154834-180204030 Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA042127, HPA056243 Uncertain Supported Golgi apparatus
Vesicles Renal cancer:1.86e-5 (unfavourable) Expressed in all Expressed in all gallbladder: 234.2 QSOX2 DKFZp762A2013, QSCN6L1, SOXN ENSG00000165661 Quiescin Q6 sulfhydryl oxidase 2 9 136206333-136245841 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA012716, HPA017280 Uncertain Validated Nucleoplasm
Golgi apparatus Renal cancer:9.64e-6 (unfavourable) Expressed in all Expressed in all lymph node: 20.9 RDH10 SDR16C4 ENSG00000121039 Retinol dehydrogenase 10 (all-trans) 8 73294612-73325281 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA049199 Approved Lipid droplets Expressed in all Expressed in all placenta: 51.3 RDH11 ARSDR1, MDT1, SDR7C1 ENSG00000072042 Retinol dehydrogenase 11 (all-trans/9-cis/11-cis) 14 67676801-67695814 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB046011 Supported Renal cancer:1.30e-7 (favourable), Head and neck cancer:2.89e-5 (unfavourable), Endometrial cancer:2.62e-4 (favourable) Tissue enriched Tissue enriched 8 prostate: 945.5 parathyroid gland: 123.3 RDH5 HSD17B9, RDH1, SDR9C5 ENSG00000135437 Retinol dehydrogenase 5 (11-cis/9-cis) 12 55720367-55724705 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA063345 Approved Vesicles
Cytosol Mixed Tissue enhanced adipose tissue: 97.7 liver: 29.9 RETSAT FLJ20296 ENSG00000042445 Retinol saturase (all-trans-retinol 13,14-reductase) 2 85342088-85354620 Enzymes, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA007961, HPA046513 Uncertain Approved Nucleoli Renal cancer:1.95e-10 (favourable), Liver cancer:4.23e-4 (favourable) Expressed in all Expressed in all adipose tissue: 264.9 RRM1 ENSG00000167325 Ribonucleotide reductase M1 11 4094707-4138876 Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB022093, HPA057265, HPA064297 Supported Validated Cytosol Liver cancer:1.53e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 59.5 RRM2 ENSG00000171848 Ribonucleotide reductase M2 2 10122328-10131419 Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA056994 Approved Supported Cytosol Renal cancer:0.00e+0 (unfavourable), Liver cancer:1.39e-5 (unfavourable), Pancreatic cancer:1.62e-4 (unfavourable) Expressed in all Mixed lymph node: 47.8 RRM2B p53R2 ENSG00000048392 Ribonucleotide reductase M2 B (TP53 inducible) 8 102204502-102239118 Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB006854, HPA028812 Approved Supported Nucleoplasm
Cytosol Expressed in all Expressed in all parathyroid gland: 73.7 SARDH DMGDHL1, SDH ENSG00000123453 Sarcosine dehydrogenase 9 133663560-133739955 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA057267, HPA058086 Supported Approved Mitochondria Glioma:3.50e-4 (unfavourable) Tissue enriched Tissue enhanced epididymis: 58.4;liver: 43.2 kidney: 12.5 SC5D SC5DL ENSG00000109929 Sterol-C5-desaturase 11 121292453-121308694 Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA066283, HPA070248 Approved Approved Nucleoplasm
Endoplasmic reticulum
Plasma membrane
Cytosol Renal cancer:1.07e-7 (favourable), Head and neck cancer:3.30e-4 (unfavourable), Melanoma:3.98e-4 (unfavourable) Expressed in all Expressed in all liver: 193.1 SCD FADS5, SCDOS ENSG00000099194 Stearoyl-CoA desaturase (delta-9-desaturase) 10 100347124-100364834 Enzymes, Predicted membrane proteins Evidence at protein level HPA012107, HPA063921 Uncertain Validated Endoplasmic reticulum Renal cancer:7.56e-5 (unfavourable), Urothelial cancer:7.79e-5 (unfavourable) Expressed in all Expressed in all adipose tissue: 1252.9 SCD5 ACOD4, FADS4, FLJ21032, HSCD5, SCD4 ENSG00000145284 Stearoyl-CoA desaturase 5 4 82629539-82798857 Enzymes, Predicted membrane proteins Evidence at protein level HPA042380 Uncertain Renal cancer:2.32e-5 (favourable) Group enriched Tissue enhanced adrenal gland: 201.7;cerebral cortex: 502.5 epididymis: 117.9 SDHA FP, SDH2, SDHF ENSG00000073578 Succinate dehydrogenase complex, subunit A, flavoprotein (Fp) 5 218241-256700 Citric acid cycle related proteins, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level CAB034929, HPA041981, HPA064582 Supported Validated Mitochondria Renal cancer:9.53e-8 (favourable), Breast cancer:6.00e-4 (unfavourable) Expressed in all Expressed in all heart muscle: 249.5 SDHB SDH, SDH1 ENSG00000117118 Succinate dehydrogenase complex, subunit B, iron sulfur (Ip) 1 17018722-17054170 Cancer-related genes, Citric acid cycle related proteins, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA002868, CAB009822, CAB068233, CAB068234, CAB068235 Supported Supported Nucleoplasm
Plasma membrane
Mitochondria Renal cancer:2.93e-7 (favourable) Expressed in all Expressed in all kidney: 213.3 SDR16C5 RDH-E2, RDHE2 ENSG00000170786 Short chain dehydrogenase/reductase family 16C, member 5 8 56300010-56320776 Enzymes, Predicted membrane proteins Evidence at protein level HPA025224 Supported Head and neck cancer:7.88e-4 (favourable) Mixed Group enriched 6 breast: 14.9;esophagus: 36.4;lung: 40.3;skin: 73.0;small intestine: 22.1;stomach: 21.3;tonsil: 26.3 cervix, uterine: 5.6 SMOX C20orf16, dJ779E11.1, FLJ20746, MGC1010, PAO, PAOh1, SMO ENSG00000088826 Spermine oxidase 20 4120980-4187747 Enzymes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level HPA047117, HPA060198 Approved Supported Nucleoplasm
Nuclear membrane
Vesicles Liver cancer:3.33e-6 (unfavourable), Renal cancer:1.06e-4 (unfavourable), Lung cancer:1.36e-4 (unfavourable) Expressed in all Tissue enhanced cerebral cortex: 49.8 gallbladder: 23.5 SOD1 ALS, ALS1, IPOA ENSG00000142168 Superoxide dismutase 1, soluble 21 31659622-31668931 Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA001401, CAB008670 Supported Supported Nucleus
Plasma membrane
Cytosol Expressed in all Expressed in all liver: 767.7 SOD2 ENSG00000112096 Superoxide dismutase 2, mitochondrial 6 159669057-159762529 Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA001814, CAB002013 Supported Renal cancer:1.72e-4 (unfavourable) Expressed in all Expressed in all appendix: 750.9 SOD3 EC-SOD ENSG00000109610 Superoxide dismutase 3, extracellular 4 24789912-24800842 Enzymes, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA042110 Supported Expressed in all Tissue enhanced adipose tissue: 179.2 fallopian tube: 66.0 SORD ENSG00000140263 Sorbitol dehydrogenase 15 45023104-45077185 Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA040260, HPA040621 Supported Approved Cytosol Liver cancer:6.14e-5 (favourable) Expressed in all Expressed in all cervix, uterine: 401.6 SPR SDR38C1 ENSG00000116096 Sepiapterin reductase (7,8-dihydrobiopterin:NADP+ oxidoreductase) 2 72887360-72892158 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA039505 Uncertain Supported Nucleoplasm
Cytosol Expressed in all Mixed parathyroid gland: 49.1 SQLE ENSG00000104549 Squalene epoxidase 8 124998497-125022283 Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA018038, HPA020762 Approved Uncertain Vesicles
Cytosol Pancreatic cancer:2.73e-4 (unfavourable), Lung cancer:4.67e-4 (unfavourable), Renal cancer:5.70e-4 (unfavourable), Head and neck cancer:7.42e-4 (unfavourable) Expressed in all Mixed testis: 107.2 SRD5A1 ENSG00000145545 Steroid-5-alpha-reductase, alpha polypeptide 1 (3-oxo-5 alpha-steroid delta 4-dehydrogenase alpha 1) 5 6633343-6674386 Cancer-related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins Evidence at protein level HPA051402 Approved Endometrial cancer:8.73e-6 (unfavourable) Expressed in all Mixed skin: 17.1 SRD5A3 FLJ13352, SRD5A2L, SRD5A2L1 ENSG00000128039 Steroid 5 alpha-reductase 3 4 55346109-55373096 Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA027006 Uncertain Approved Plasma membrane
Cytosol Renal cancer:4.85e-10 (unfavourable), Liver cancer:1.80e-6 (unfavourable), Endometrial cancer:9.39e-4 (favourable) Expressed in all Expressed in all gallbladder: 28.3 SUOX ENSG00000139531 Sulfite oxidase 12 55997180-56006641 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA038208, HPA038209 Approved Renal cancer:4.77e-7 (favourable), Urothelial cancer:8.32e-5 (favourable), Pancreatic cancer:6.28e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 106.1 TDO2 TDO, TPH2 ENSG00000151790 Tryptophan 2,3-dioxygenase 4 155854738-155920406 Enzymes, Predicted intracellular proteins Evidence at protein level HPA039611 Uncertain Uncertain Plasma membrane
Cytosol Tissue enriched Tissue enriched 17 liver: 277.5 appendix: 16.2 TECR GPSN2, MRT14, SC2, TER ENSG00000099797 Trans-2,3-enoyl-CoA reductase 19 14517085-14565980 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA029780, HPA056488 Supported Supported Endoplasmic reticulum Urothelial cancer:2.60e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 397.0 TET1 bA119F7.1, CXXC6, KIAA1676, LCX ENSG00000138336 Tet methylcytosine dioxygenase 1 10 68560656-68694482 Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB014886, HPA019032, HPA057273 Approved Supported Nucleus
Nuclear membrane Tissue enriched Mixed parathyroid gland: 2.4 TET2 FLJ20032, KIAA1546 ENSG00000168769 Tet methylcytosine dioxygenase 2 4 105145875-105279816 Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA043135 Supported Approved Nucleoplasm Mixed Mixed bone marrow: 15.8 TET3 hCG_40738, MGC22014 ENSG00000187605 Tet methylcytosine dioxygenase 3 2 73986404-74108176 Enzymes, Predicted intracellular proteins Evidence at protein level HPA050845 Approved Approved Nucleoplasm
Vesicles
Cytosol Renal cancer:3.58e-5 (unfavourable) Expressed in all Mixed skin: 18.0 TH DYT5b ENSG00000180176 Tyrosine hydroxylase 11 2163929-2171877 Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level CAB002522, HPA061003, CAB072340 Supported Supported Tissue enhanced Tissue enriched 81 adrenal gland: 261.2 adipose tissue: 3.2 TM7SF2 ANG1, DHCR14A, NET47 ENSG00000149809 Transmembrane 7 superfamily member 2 11 65111845-65116384 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA030691, HPA072704 Approved Supported Endoplasmic reticulum
Vesicles Renal cancer:8.49e-8 (favourable) Expressed in all Expressed in all adrenal gland: 161.3 TMLHE BBOX2, FLJ10727, TMLH, XAP130 ENSG00000185973 Trimethyllysine hydroxylase, epsilon X 155490115-155669944 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA034589, HPA040331 Approved Supported Mitochondria Renal cancer:3.68e-6 (favourable) Expressed in all Expressed in all parathyroid gland: 30.8 TPH1 TPH, TPRH ENSG00000129167 Tryptophan hydroxylase 1 11 18017564-18042426 Enzymes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level CAB010767, HPA022483 Supported Uncertain Cytosol Mixed Group enriched 6 colon: 9.0;duodenum: 10.5;rectum: 21.3;small intestine: 12.9;stomach: 15.5 prostate: 2.2 TPH2 FLJ37295, NTPH ENSG00000139287 Tryptophan hydroxylase 2 12 71938846-72186618 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level CAB078198 Supported Not detected Tissue enhanced cerebral cortex: 1.0 testis: 0.2 TPO TPX ENSG00000115705 Thyroid peroxidase 2 1374223-1543711 Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA007987, CAB009587 Supported Tissue enriched Tissue enriched 101 thyroid gland: 1811.8 spleen: 17.9 TSTA3 FX, P35B, SDR4E1 ENSG00000104522 Tissue specific transplantation antigen P35B 8 143612618-143618048 Enzymes, Predicted intracellular proteins Evidence at protein level HPA023361 Approved Approved Nucleoplasm
Cytosol Renal cancer:1.59e-4 (unfavourable), Ovarian cancer:2.41e-4 (favourable) Expressed in all Expressed in all stomach: 50.8 TXNRD1 GRIM-12, Trxr1, TXNR ENSG00000198431 Thioredoxin reductase 1 12 104215779-104350305 Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA001395, CAB004607, CAB015834, HPA043871 Approved Supported Nucleus Liver cancer:1.12e-5 (unfavourable), Renal cancer:1.20e-5 (unfavourable) Expressed in all Expressed in all adrenal gland: 109.8 TXNRD2 TR, TR3, TRXR2 ENSG00000184470 Thioredoxin reductase 2 22 19875517-19941992 Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB002007, HPA003323 Supported Supported Mitochondria
Cytosol Renal cancer:1.10e-7 (favourable) Expressed in all Expressed in all adrenal gland: 34.4 TYR OCA1, OCA1A, OCAIA ENSG00000077498 Tyrosinase 11 89177452-89295759 Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins Evidence at protein level CAB000079, HPA043241, HPA050889 Supported Validated Vesicles Tissue enriched Tissue enriched 33 skin: 29.9 breast: 0.9 TYW5 C2orf60, FLJ37953 ENSG00000162971 TRNA-yW synthesizing protein 5 2 199929975-199955736 Enzymes, Predicted intracellular proteins Evidence at protein level HPA028294, HPA045803 Uncertain Approved Nuclear bodies Expressed in all Mixed appendix: 1.6 UGDH ENSG00000109814 UDP-glucose 6-dehydrogenase 4 39498755-39528311 Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB034444, HPA036656, HPA036657 Supported Validated Nucleoplasm Renal cancer:5.51e-10 (unfavourable) Expressed in all Expressed in all colon: 97.7 UQCRFS1 RIP1, RIS1, RISP, UQCR5 ENSG00000169021 Ubiquinol-cytochrome c reductase, Rieske iron-sulfur polypeptide 1 19 29205321-29213541 Enzymes, Predicted intracellular proteins Evidence at protein level HPA041863, HPA050339 Supported Validated Mitochondria Renal cancer:3.92e-9 (favourable), Colorectal cancer:3.29e-4 (favourable), Ovarian cancer:3.84e-4 (unfavourable) Expressed in all Expressed in all skeletal muscle: 70.9 VKORC1 VKCFD2 ENSG00000167397 Vitamin K epoxide reductase complex, subunit 1 16 31090842-31095980 Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA042720 Approved Renal cancer:2.09e-10 (unfavourable) Expressed in all Expressed in all liver: 141.1 VKORC1L1 ENSG00000196715 Vitamin K epoxide reductase complex, subunit 1-like 1 7 65873267-65959563 Enzymes, FDA approved drug targets, Predicted membrane proteins Evidence at protein level HPA053954 Approved Supported Endoplasmic reticulum Expressed in all Expressed in all adipose tissue: 57.3 XDH XO, XOR ENSG00000158125 Xanthine dehydrogenase 2 31334321-31414715 Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA062641, HPA069323 Supported Supported Nucleus Urothelial cancer:8.73e-6 (favourable) Mixed Tissue enhanced breast: 48.6;duodenum: 46.9;liver: 35.9;small intestine: 55.8 colon: 11.4